Header Logo

ELIZABETH ANN MITTENDORF

TitleAssociate Professor
InstitutionMD Anderson
DepartmentBreast Surgical Oncology
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Shah C, Whitworth P, Vicini FA, Narod S, Gerber N, Jhawar SR, King TA, Mittendorf EA, Willey SC, Rabinovich R, Gold L, Brown E, Patel A, Vargo J, Barry PN, Rock D, Friedman N, Bedi G, Templeton S, Brown S, Gabordi R, Riley L, Lee L, Baron P, Majithia L, Mirabeau-Beale KL, Reid VJ, Hirsch A, Hwang C, Pellicane J, Maganini R, Khan S, MacDermed DM, Small W, Mittal K, Borgen P, Cox C, Shivers SC, Bremer T. ASO Visual Abstract: The Clinical Utility of a 7-Gene Biosignature on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery: An Updated Analysis of the DCISionRT? PREDICT Study. Ann Surg Oncol. 2024 Jul 15. PMID: 39008205.
      Citations:    
    2. Tarantino P, Tayob N, Villacampa G, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Garrett AM, Marcom PK, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Ruddy KJ, Waks AG, DeMeo M, Burstein HJ, Partridge AH, Dell'Orto P, Russo L, Krause E, Newhouse DJ, Kurt BB, Mittendorf EA, Schneider B, Prat A, Winer EP, Krop IE, Tolaney SM, Consortium of the TBCRC Translational Investigators, TBCRC Translational Investigators. Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT. J Clin Oncol. 2024 Jun 27; JCO2302170. PMID: 38935923.
      Citations:    Fields:    
    3. Shah C, Whitworth P, Vicini FA, Narod S, Gerber N, Jhawar SR, King TA, Mittendorf EA, Willey SC, Rabinovich R, Gold L, Brown E, Patel A, Vargo J, Barry PN, Rock D, Friedman N, Bedi G, Templeton S, Brown S, Gabordi R, Riley L, Lee L, Baron P, Majithia L, Mirabeau-Beale KL, Reid VJ, Hirsch A, Hwang C, Pellicane J, Maganini R, Khan S, MacDermed DM, Small W, Mittal K, Borgen P, Cox C, Shivers SC, Bremer T. The Clinical Utility of a 7-Gene Biosignature on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery: An Updated Analysis of the DCISionRT? PREDICT Study. Ann Surg Oncol. 2024 Jun 25. PMID: 38916700.
      Citations: 1     Fields:    
    4. Schlam I, Corti C, Sammons S, Mittendorf EA, Tolaney SM. Checkpoint inhibition for early-stage hormone receptor-positive breast cancer. Expert Opin Biol Ther. 2024 Jun; 24(6):511-520. PMID: 38913933.
      Citations:    Fields:    Translation:Humans
    5. Myers SP, Laws A, Dominici LS, Lagendijk M, Grossmith S, Mittendorf EA, King TA. Arm morbidity and financial difficulty in breast cancer survivors. J Cancer Surviv. 2024 Jun 19. PMID: 38896173.
      Citations:    Fields:    
    6. Park KU, Padamsee TJ, Birken SA, Lee S, Niles K, Blair SL, Grignol V, Dickson-Witmer D, Nowell K, Neuman H, King T, Mittendorf E, Paskett ED, Brindle M. Factors Influencing Implementation of the Commission on Cancer's Breast Synoptic Operative Report (Alliance A20_Pilot9). Ann Surg Oncol. 2024 Jun 11. PMID: 38862840.
      Citations:    Fields:    
    7. Minami CA, Jin G, Freedman RA, Schonberg MA, King TA, Mittendorf EA. Physician-level variation in axillary surgery in older adults with T1N0 hormone receptor-positive breast cancer: A retrospective population-based cohort study. J Geriatr Oncol. 2024 Jun; 15(5):101795. PMID: 38759256; PMCID: PMC11225423.
      Citations:    Fields:    Translation:Humans
    8. King TA, Mittendorf EA. Breast Articles From 2023: Informing Practice Across the Continuum of Care. Ann Surg Oncol. 2024 Jul; 31(7):4470-4476. PMID: 38734863.
      Citations:    Fields:    Translation:Humans
    9. Leonard S, Jones AN, Newman L, Chavez-MacGregor M, Freedman RA, Mayer EL, Mittendorf EA, King TA, Kantor O. Racial disparities in outcomes of patients with stage I-III triple-negative breast cancer after adjuvant chemotherapy: a post-hoc analysis of the E5103 randomized trial. Breast Cancer Res Treat. 2024 Jul; 206(1):185-193. PMID: 38649618.
      Citations:    Fields:    Translation:Humans
    10. Morganti S, Jin Q, Vincuilla J, Buehler R, Ryan S, Stokes S, Parker T, Mittendorf EA, King TA, Weiss A, Partridge AH, Bychkovsky BL, Curigliano G, Tayob N, Lin NU, Garber JE, Tolaney SM, Lynce F. Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer. NPJ Breast Cancer. 2024 Apr 16; 10(1):28. PMID: 38627457; PMCID: PMC11021554.
      Citations:    
    11. Baker GJ, Novikov E, Zhao Z, Vallius T, Davis JA, Lin JR, Muhlich JL, Mittendorf EA, Santagata S, Guerriero JL, Sorger PK. Quality Control for Single Cell Analysis of High-plex Tissue Profiles using CyLinter. bioRxiv. 2024 Mar 22. PMID: 37961235; PMCID: PMC10634977.
      Citations:    
    12. Garber HR, Basu S, Jindal S, He Z, Chu K, Raghavendra AS, Yam C, Santiago L, Adrada BE, Sharma P, Mittendorf EA, Litton JK. Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancer. Oncotarget. 2024 Mar 19; 15:238-247. PMID: 38502947; PMCID: PMC10950364.
      Citations:    Fields:    Translation:Humans
    13. Basho RK, Zhao L, White JB, Huo L, Bassett RL, Mittendorf EA, Thompson A, Litton JK, Ueno N, Arun B, Lim B, Valero V, Tripathy D, Zhang J, Adrada BE, Santiago L, Ravenberg E, Seth S, Yam C, Moulder SL, Damodaran S. Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes. JCO Precis Oncol. 2024 Mar; 8:e2300124. PMID: 38484209; PMCID: PMC10954064.
      Citations:    Fields:    Translation:Humans
    14. Goldberg J, Qiao N, Guerriero JL, Gross B, Meneksedag Y, Lu YF, Philips AV, Rahman T, Meric-Bernstam F, Roszik J, Chen K, Jeselsohn R, Tolaney SM, Peoples GE, Alatrash G, Mittendorf EA. Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast Cancer. Cancer Res Commun. 2024 02 22; 4(2):496-504. PMID: 38335301; PMCID: PMC10883292.
      Citations:    Translation:Humans
    15. Tarantino P, Ajari O, Graham N, Vincuilla J, Parker T, Hughes ME, Tayob N, Garrido-Castro AC, Morganti S, King TA, Mittendorf EA, Curigliano G, Lin NU, Tolaney SM. Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer. Eur J Cancer. 2024 Apr; 201:113920. PMID: 38368741.
      Citations: 1     Fields:    Translation:Humans
    16. Lynce F, Stevens LE, Li Z, Brock JE, Gulvady A, Huang Y, Nakhlis F, Patel A, Force JM, Haddad TC, Ueno N, Stearns V, Wolff AC, Clark AS, Bellon JR, Richardson ET, Balko JM, Krop IE, Winer EP, Lange P, Hwang ES, King TA, Tolaney SM, Thompson A, Gupta GP, Mittendorf EA, Regan MM, Overmoyer B, Polyak K. TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer. Breast Cancer Res. 2024 01 31; 26(1):20. PMID: 38297352; PMCID: PMC10829369.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    17. Morganti S, Gibson CJ, Jin Q, Santos K, Patel A, Wilson A, Merrill M, Vincuilla J, Stokes S, Lipsyc-Sharf M, Parker T, King TA, Mittendorf EA, Curigliano G, Hughes ME, Stover DG, Tolaney SM, Weeks LD, Tayob N, Lin NU, Garber JE, Miller PG, Parsons HA. Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer. J Clin Oncol. 2024 Jan 08; JCO2301071. PMID: 38190580.
      Citations:    Fields:    
    18. Guerriero JL, Lin JR, Pastorello RG, Du Z, Chen YA, Townsend MG, Shimada K, Hughes ME, Ren S, Tayob N, Zheng K, Mei S, Patterson A, Taneja KL, Metzger O, Tolaney SM, Lin NU, Dillon DA, Schnitt SJ, Sorger PK, Mittendorf EA, Santagata S. Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer. NPJ Breast Cancer. 2024 Jan 02; 10(1):2. PMID: 38167908; PMCID: PMC10761880.
      Citations:    
    19. Higgins T, Kantor O, Harrison B, Giordano J, McGrath M, Burstein HJ, Schnitt SJ, Rahman T, Vora H, Garrido-Castro A, Tolaney SM, Meric-Bernstam F, King TA, Mittendorf EA. Defining the Biology of Estrogen Receptor-Low-Positive Breast Cancer. Ann Surg Oncol. 2024 Apr; 31(4):2244-2252. PMID: 38161200.
      Citations: 1     Fields:    Translation:Humans
    20. Laws A, Lagendijk M, Grossmith S, Hughes M, Lin NU, Mittendorf EA, Eliassen AH, King TA, Dominici LS. Long-Term Patient-Reported Arm Symptoms in Breast Cancer Survivors. Ann Surg Oncol. 2024 Mar; 31(3):1623-1633. PMID: 38071708.
      Citations:    Fields:    Translation:Humans
    21. Zeiger MA, ASA Task Force for Research Sustainability, Ladner DP, Goldstein AM, Billiar TR, Cameron AM, Carpizo DR, Coopersmith CM, DeMatteo RP, Feng S, Gallagher KA, Gillanders WE, Lal BK, Lipshutz GS, Chu DI, Liu A, Maier RV, Mittendorf EA, Morris AM, Sicklick JK, Velazquez OC, Whitson BA, Wilke LG, Yoon SS, Farmer DL, Hwang ES. Transforming the Future of Surgeon-Scientists. Ann Surg. 2024 Feb 01; 279(2):231-239. PMID: 37916404.
      Citations:    Fields:    Translation:Humans
    22. Minami CA, Jin G, Freedman RA, Schonberg MA, King TA, Mittendorf EA. Trends in Locoregional Therapy in Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer by Frailty and Life Expectancy. Ann Surg Oncol. 2024 Feb; 31(2):920-930. PMID: 37851196; PMCID: PMC10826462.
      Citations:    Fields:    Translation:Humans
    23. Hermida-Prado F, Xie Y, Sherman S, Nagy Z, Russo D, Akhshi T, Chu Z, Feit A, Campisi M, Chen M, Nardone A, Guarducci C, Lim K, Font-Tello A, Lee I, Garc?a-Pedrero J, Ca?adas I, Agudo J, Huang Y, Sella T, Jin Q, Tayob N, Mittendorf EA, Tolaney SM, Qiu X, Long H, Symmans WF, Lin JR, Santagata S, Bedrosian I, Yardley DA, Mayer IA, Richardson ET, Oliveira G, Wu CJ, Schuster EF, Dowsett M, Welm AL, Barbie D, Metzger O, Jeselsohn R. Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer. Cancer Res. 2023 10 02; 83(19):3284-3304. PMID: 37450351; PMCID: PMC10543960.
      Citations:    Fields:    Translation:HumansCells
    24. Kantor O, King TA, Jones A, Glass C, Leonard SJ, Ogayo ER, Mayer EL, Chavez-MacGregor M, Newman LA, Freedman RA, Mittendorf EA. Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS: A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical Trial. Ann Surg Oncol. 2023 Dec; 30(13):8404-8411. PMID: 37777685.
      Citations:    Fields:    Translation:Humans
    25. Glass CC, Pride RM, Freedman RA, Mayer EL, Ogayo ER, Chavez-MacGregor M, King TA, Mittendorf EA, Kantor O. Racial Disparities in Locoregional Recurrence in Postmenopausal Patients with Stage I-III, Hormone Receptor-Positive Breast Cancer Enrolled in the NSABP B-42 Clinical Trial. Ann Surg Oncol. 2023 Dec; 30(13):8320-8326. PMID: 37670122.
      Citations: 1     Fields:    Translation:Humans
    26. King CB, Bychkovsky BL, Warner ET, King TA, Freedman RA, Mittendorf EA, Katlin F, Revette A, Crookes DM, Maniar N, Pace LE. Inequities in referrals to a breast cancer risk assessment and prevention clinic: a mixed methods study. BMC Prim Care. 2023 08 25; 24(1):165. PMID: 37626335; PMCID: PMC10464083.
      Citations:    Fields:    Translation:Humans
    27. Mayerhofer C, Sedrak MS, Hopkins JO, Li T, Tayob N, Faggen MG, Sinclair NF, Chen WY, Parsons HA, Wong AR, Tiwari A, McAllister SS, Mittendorf EA, Gibson CJ, Burstein HJ, Kim AS, Freedman RA, Mayer EL, Lange PB, Basta AS, Perilla-Glen A, Lederman RI, Miller PG. Clonal hematopoiesis in older patients with breast cancer receiving chemotherapy. J Natl Cancer Inst. 2023 08 08; 115(8):981-988. PMID: 37042724; PMCID: PMC10407695.
      Citations: 1     Fields:    Translation:Humans
    28. Chen H, Ding Q, Khazai L, Zhao L, Damodaran S, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Lim B, Thompson AM, Mittendorf EA, Adrada B, Virani K, White JB, Ravenberg E, Song X, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Routbort MJ, Sahin A, Valero V, Symmans WF, Tripathy D, Wang WL, Moulder S, Huo L. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol. 2023; 15:17588359231189422. PMID: 37547448; PMCID: PMC10399250.
      Citations:    
    29. Pride RM, Glass CC, Nakhlis F, Laws A, Weiss AC, Bellon JR, Mittendorf EA, King TA, Kantor O. Intraoperative Pathology Assessment May Lead to Overtreatment of the Axilla in Clinically Node-Negative Breast Cancer Patients Undergoing Upfront Mastectomy. Ann Surg Oncol. 2023 Oct; 30(10):5978-5987. PMID: 37436607.
      Citations: 1     Fields:    Translation:Humans
    30. Abuhadra N, Sun R, Yam C, Rauch GM, Ding Q, Lim B, Thompson AM, Mittendorf EA, Adrada BE, Damodaran S, Virani K, White J, Ravenberg E, Sun J, Choi J, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin A, Valero V, Symmans WF, Litton JK, Tripathy D, Moulder S, Huo L. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel). 2023 Jun 21; 15(13). PMID: 37444385; PMCID: PMC10339918.
      Citations: 1     
    31. Downs-Canner S, Mittendorf EA. Selecting Triple Negative Breast Cancer Patients for Immunotherapy. Surg Oncol Clin N Am. 2023 10; 32(4):733-745. PMID: 37714640.
      Citations:    Fields:    Translation:Humans
    32. O'Shea AE, Clifton GT, Qiao N, Heckman-Stoddard BM, Wojtowicz M, Dimond E, Bedrosian I, Weber D, Garber JE, Husband A, Pastorello R, Lee JJ, Hernandez M, Liu DD, Vornik LA, Brown PH, Alatrash G, Peoples GE, Mittendorf EA. Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ. Cancer Prev Res (Phila). 2023 06 01; 16(6):333-341. PMID: 37259799; PMCID: PMC10903526.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    33. Kantor O, King TA, Freedman RA, Mayer EL, Chavez-MacGregor M, Korde LA, Sparano JA, Mittendorf EA. Racial and Ethnic Disparities in Locoregional Recurrence Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer: A Post Hoc Analysis of the TAILORx Randomized Clinical Trial. JAMA Surg. 2023 06 01; 158(6):583-591. PMID: 37043210; PMCID: PMC10099173.
      Citations: 3     Fields:    Translation:Humans
    34. Bueno-Mui?o C, Echavarr?a I, L?pez-Tarruella S, Roche-Molina M, Del Monte-Mill?n M, Massarrah T, Jerez Y, Ayala de la Pe?a F, Garc?a-S?enz J?, Moreno F, Rodr?guez-Lescure ?, Mal?n-Gim?nez D, Ballesteros Garc?a AI, Mar?n-Aguilera M, Galv?n P, Bras?-Maristany F, Waks AG, Tolaney SM, Mittendorf EA, Vivancos A, Villagrasa P, Parker JS, Perou CM, Par? L, Villacampa G, Prat A, Mart?n M. Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab. JAMA Oncol. 2023 06 01; 9(6):841-846. PMID: 37103916; PMCID: PMC10141274.
      Citations: 2     Fields:    Translation:Humans
    35. Waks AG, Ogayo ER, Par? L, Mar?n-Aguilera M, Bras?-Maristany F, Galv?n P, Castillo O, Mart?nez-S?ez O, Vivancos A, Villagrasa P, Villacampa G, Tarantino P, Desai N, Guerriero J, Metzger O, Tung NM, Krop IE, Parker JS, Perou CM, Prat A, Winer EP, Tolaney SM, Mittendorf EA. Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab. JAMA Oncol. 2023 06 01; 9(6):835-840. PMID: 37103927; PMCID: PMC10141272.
      Citations: 3     Fields:    Translation:Humans
    36. Downs-Canner S, Mittendorf EA. Correction: Preoperative Immunotherapy Combined with Chemotherapy for Triple-Negative Breast Cancer: Perspective on the KEYNOTE-522 Study. Ann Surg Oncol. 2023 Jun; 30(6):3286. PMID: 37014560.
      Citations: 1     Fields:    
    37. Minami CA, Jin G, Freedman RA, Schonberg MA, King TA, Mittendorf EA. Association of Surgery With Frailty Status in Older Women With Early-Stage Breast Cancer. JAMA Surg. 2023 06 01; 158(6):664-666. PMID: 36920410; PMCID: PMC10018401.
      Citations:    Fields:    Translation:Humans
    38. Weiss A, Li T, Desai NV, Tung NM, Poorvu PD, Partridge AH, Nakhlis F, Dominici L, Sinclair N, Spring LM, Faggen M, Constantine M, Krop IE, DeMeo M, Wrabel E, Alberti J, Chikarmane S, Tayob N, King TA, Tolaney SM, Winer EP, Mittendorf EA, Waks AG. Impact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial. J Am Coll Surg. 2023 08 01; 237(2):247-256. PMID: 37194964.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    39. Trapani D, Jin Q, Block CC, Freedman RA, Lin NU, Tarantino P, Mittendorf EA, King TA, Lester SC, Brock JE, Tayob N, Bunnell CA, Tolaney SM, Burstein HJ. Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor-Positive Breast Cancer: Implications for Guidance and Reimbursement. JCO Oncol Pract. 2023 08; 19(8):560-570. PMID: 37192427.
      Citations:    Fields:    Translation:Humans
    40. Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, Ramirez D, Karuturi M, Layman RM, Ibrahim N, Rauch GM, Adrada BE, Candelaria RP, White JB, Ravenberg E, Clayborn A, Ding QQ, Symmans WF, Prabhakaran S, Thompson AM, Valero V, Tripathy D, Huo L, Moulder SL, Litton JK. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat. 2023 Jun; 199(3):457-469. PMID: 37061619.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    41. Higgins T, Mittendorf EA. Peritumoral Lidocaine Injection: A Low-Cost, Easily Implemented Intervention to Improve Outcomes in Early-Stage Breast Cancer. J Clin Oncol. 2023 06 20; 41(18):3287-3290. PMID: 37023390.
      Citations:    Fields:    Translation:Humans
    42. Weiss A, Mart?nez-S?ez O, Waks AG, Laws A, McGrath M, Tarantino P, Portnow L, Winer E, Rey M, Tapia M, Prat A, Partridge AH, Tolaney SM, Cejalvo JM, Mittendorf EA, King TA. Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohorts. Cancer. 2023 06 15; 129(12):1836-1845. PMID: 36951169.
      Citations:    Fields:    Translation:Humans
    43. Downs-Canner S, Mittendorf EA. Preoperative Immunotherapy Combined with Chemotherapy for Triple-Negative Breast Cancer: Perspective on the KEYNOTE-522 Study. Ann Surg Oncol. 2023 06; 30(6):3166-3169. PMID: 36897418.
      Citations: 1     Fields:    Translation:Humans
    44. Portnow LH, Kochkodan-Self JM, Maduram A, Barrios M, Onken AM, Hong X, Mittendorf EA, Giess CS, Chikarmane SA. Multimodality Imaging Review of HER2-positive Breast Cancer and Response to Neoadjuvant Chemotherapy. Radiographics. 2023 02; 43(2):e220103. PMID: 36633970.
      Citations: 2     Fields:    
    45. Zimbalist AS, Caan BJ, Chen WY, Mittendorf EA, Dillon DAR, Quesenberry C, Cespedes Feliciano EM. Metabolic abnormalities and survival among patients with non-metastatic breast cancer. BMC Cancer. 2022 Dec 29; 22(1):1361. PMID: 36581817; PMCID: PMC9801571.
      Citations:    Fields:    Translation:Humans
    46. Roweth HG, Malloy MW, Goreczny GJ, Becker IC, Guo Q, Mittendorf EA, Italiano JE, McAllister SS, Battinelli EM. Pro-inflammatory megakaryocyte gene expression in murine models of breast cancer. Sci Adv. 2022 10 14; 8(41):eabo5224. PMID: 36223471; PMCID: PMC9555784.
      Citations:    Fields:    Translation:AnimalsCells
    47. Lyu HG, Kantor O, Laws AD, McDonald J, Pham L, Dominici LS, Vincuilla J, Raut CP, Danilchuk B, Novak L, Parker T, King TA, Mittendorf EA. Development of an Electronic Health Record Registry to Facilitate Collection of Commission on Cancer Metrics for Patients Undergoing Surgery for Breast Cancer. JCO Clin Cancer Inform. 2022 10; 6:e2200012. PMID: 36215674.
      Citations:    Fields:    Translation:Humans
    48. Waks AG, Keenan TE, Li T, Tayob N, Wulf GM, Richardson ET, Attaya V, Anderson L, Mittendorf EA, Overmoyer B, Winer EP, Krop IE, Agudo J, Van Allen EM, Tolaney SM. Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer. J Immunother Cancer. 2022 10; 10(10). PMID: 36252998; PMCID: PMC9577940.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    49. Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari N, Reissfelder C, Pilarsky C, Fraga MF, Piwnica-Worms D, Kalluri R. Author Correction: Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2022 Oct; 610(7932):E15-E17. PMID: 36198804.
      Citations:    Fields:    
    50. Freedman RA, Li T, Sedrak MS, Hopkins JO, Tayob N, Faggen MG, Sinclair NF, Chen WY, Parsons HA, Mayer EL, Lange PB, Basta AS, Perilla-Glen A, Lederman RI, Wong A, Tiwari A, McAllister SS, Mittendorf EA, Miller PG, Gibson CJ, Burstein HJ. 'ADVANCE' (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer. J Geriatr Oncol. 2023 Jan; 14(1):101377. PMID: 36163163; PMCID: PMC10080267.
      Citations: 1     Fields:    Translation:Humans
    51. Barrios CH, Saji S, Harbeck N, Zhang H, Jung KH, Patel S, Patel S, Duc AN, Liste-Hermoso M, Chui SY, Mittendorf EA. Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer. NPJ Breast Cancer. 2022 Sep 19; 8(1):108. PMID: 36123366; PMCID: PMC9485121.
      Citations:    
    52. Kumar T, Hobbs E, Yang F, Chang JT, Contreras A, Cuentas ERP, Garber H, Lee S, Lu Y, Scoggins ME, Adrada BE, Whitman GJ, Arun BK, Mittendorf EA, Litton JK. Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation. Clin Cancer Res. 2022 09 01; 28(17):3669-3676. PMID: 35736816; PMCID: PMC9444971.
      Citations:    Fields:    
    53. Mittendorf EA, Kantor O, Weiss A, Richardson E, Garrido-Castro A, Portnow LH, Krop IE, Lin NU, Winer EP, Tolaney SM, King TA. Nodal Positivity in Early-Stage Triple-Negative Breast Cancer: Implications for Preoperative Immunotherapy. Ann Surg Oncol. 2023 Jan; 30(1):100-106. PMID: 35941343.
      Citations:    
    54. Minami CA, Bryan AF, Freedman RA, Revette AC, Schonberg MA, King TA, Mittendorf EA. Assessment of Oncologists' Perspectives on Omission of Sentinel Lymph Node Biopsy in Women 70 Years and Older With Early-Stage Hormone Receptor-Positive Breast Cancer. JAMA Netw Open. 2022 08 01; 5(8):e2228524. PMID: 36001314; PMCID: PMC9403774.
      Citations:    
    55. Tarantino P, Jin Q, Tayob N, Jeselsohn RM, Schnitt SJ, Vincuilla J, Parker T, Tyekucheva S, Li T, Lin NU, Hughes ME, Weiss AC, King TA, Mittendorf EA, Curigliano G, Tolaney SM. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. JAMA Oncol. 2022 08 01; 8(8):1177-1183. PMID: 35737367; PMCID: PMC9227690.
      Citations: 1     Fields:    
    56. Pernas S, Guerriero JL, Naumenko S, Goel S, Regan MM, Hu J, Harrison BT, Lynce F, Lin NU, Partridge A, Morikawa A, Hutchinson J, Mittendorf EA, Sokolov A, Overmoyer B. Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer. Ther Adv Med Oncol. 2022; 14:17588359221113269. PMID: 35923923; PMCID: PMC9340890.
      Citations:    
    57. Weiss A, King C, Vincuilla J, Parker T, Portnow L, Nakhlis F, Dominici L, Mittendorf EA, King TA. Rates of pathologic nodal disease among cN0 and cN1 patients undergoing routine axillary ultrasound and neoadjuvant chemotherapy. Breast Cancer Res Treat. 2022 Sep; 195(2):181-189. PMID: 35900704.
      Citations:    Fields:    
    58. Kantor O, Burstein HJ, King TA, Shak S, Russell CA, Giuliano AE, Hortobagyi GN, Winer EP, Korde LA, Sparano JA, Mittendorf EA. Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx. Ann Surg Oncol. 2022 Dec; 29(13):8016-8023. PMID: 35900648.
      Citations:    Fields:    
    59. Aldrich MB, Rasmussen JC, DeSnyder SM, Woodward WA, Chan W, Sevick-Muraca EM, Mittendorf EA, Smith BD, Stauder MC, Strom EA, Perkins GH, Hoffman KE, Mitchell MP, Barcenas CH, Isales LE, Shaitelman SF. Prediction of breast cancer-related lymphedema by dermal backflow detected with near-infrared fluorescence lymphatic imaging. Breast Cancer Res Treat. 2022 Aug; 195(1):33-41. PMID: 35816269; PMCID: PMC9272652.
      Citations:    Fields:    
    60. Laws A, Pastorello R, Dey T, Grossmith S, King C, McGrath M, Schnitt SJ, Mittendorf EA, King T. Impact of the Histologic Pattern of Residual Tumor After Neoadjuvant Chemotherapy on Recurrence and Survival in Stage I-III Breast Cancer. Ann Surg Oncol. 2022 Nov; 29(12):7726-7736. PMID: 35810224.
      Citations:    Fields:    
    61. Forman J, Collier K, Weber ZT, Jammihal TR, Kao KZ, Richardson ET, Keenan T, Cohen O, Manos MP, Brennick RC, Ott PA, Hodi FS, Dillon DA, Attaya V, O'Meara T, Lin NU, Van Allen EM, Rodig S, Winer EP, Mittendorf EA, Wu CJ, Wagle N, Stover DG, Shukla SA, Tolaney SM, Barroso-Sousa R. Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. JCO Precis Oncol. 2022 07; 6:e2100413. PMID: 35797509; PMCID: PMC9848556.
      Citations:    Fields:    Translation:Humans
    62. Yam C, Abuhadra N, Sun R, Adrada BE, Ding QQ, White JB, Ravenberg EE, Clayborn AR, Valero V, Tripathy D, Damodaran S, Arun BK, Litton JK, Ueno NT, Murthy RK, Lim B, Baez L, Li X, Buzdar AU, Hortobagyi GN, Thompson AM, Mittendorf EA, Rauch GM, Candelaria RP, Huo L, Moulder SL, Chang JT. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clin Cancer Res. 2022 07 01; 28(13):2878-2889. PMID: 35507014; PMCID: PMC9250637.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    63. Kantor O, Weiss A, Burstein HJ, Mittendorf EA, King TA. Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer with One to Three Positive Sentinel Lymph Nodes. Ann Surg Oncol. 2022 Nov; 29(12):7674-7682. PMID: 35763229.
      Citations:    Fields:    
    64. Burton EM, Amaria RN, Cascone T, Chalabi M, Gross ND, Mittendorf EA, Scolyer RA, Sharma P, Ascierto PA. Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021. J Transl Med. 2022 06 15; 20(1):271. PMID: 35706041; PMCID: PMC9199148.
      Citations:    Fields:    Translation:Humans
    65. Mittendorf EA, King TA, Tolaney SM. Impact of RxPONDER and monarchE on the Surgical Management of the Axilla in Patients With Breast Cancer. J Clin Oncol. 2022 10 10; 40(29):3361-3364. PMID: 35675571.
      Citations:    Fields:    
    66. Waks AG, Desai NV, Li T, Poorvu PD, Partridge AH, Sinclair N, Spring LM, Faggen M, Constantine M, Metzger O, Alberti J, Deane J, Rosenberg SM, Frank E, Tolaney SM, Krop IE, Tung NM, Tayob N, King TA, Mittendorf EA, Winer EP. A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer. NPJ Breast Cancer. 2022 May 10; 8(1):63. PMID: 35538105; PMCID: PMC9091255.
      Citations:    
    67. Baldominos P, Barbera-Mourelle A, Barreiro O, Huang Y, Wight A, Cho JW, Zhao X, Estivill G, Adam I, Sanchez X, McCarthy S, Schaller J, Khan Z, Ruzo A, Pastorello R, Richardson ET, Dillon D, Montero-Llopis P, Forman J, Shukla SA, Tolaney SM, Mittendorf EA, von Andrian UH, Wucherpfennig KW, Hemberg M, Agudo J, Barroso-Sousa R. Quiescent cancer cells resist T?cell attack by forming an immunosuppressive niche. Cell. 2022 05 12; 185(10):1694-1708.e19. PMID: 35447074.
      Citations: 3     Fields:    Translation:HumansCells
    68. Minami CA, Jin G, Schonberg MA, Freedman RA, King TA, Mittendorf EA. Variation in Deescalated Axillary Surgical Practices in Older Women with Early-Stage Breast Cancer. Ann Surg Oncol. 2022 Apr 06. PMID: 35385998; PMCID: PMC9982465.
      Citations:    Fields:    
    69. Mittendorf EA, Burgers F, Haanen J, Cascone T. Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-15. PMID: 35714302.
      Citations:    Fields:    Translation:Humans
    70. Tarantino P, Curigliano G, Parsons HA, Lin NU, Krop I, Mittendorf EA, Waks A, Winer EP, Tolaney SM. Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer: A Review. JAMA Oncol. 2022 04 01; 8(4):629-635. PMID: 35024766.
      Citations:    Fields:    Translation:Humans
    71. Song JH, Kantor O, Mittendorf EA, King TA, Minami CA. Race and Site of Care Impact Treatment Delays in Older Women with Non-Metastatic Breast Cancer. Ann Surg Oncol. 2022 Mar 30. PMID: 35353260; PMCID: PMC11225422.
      Citations:    Fields:    
    72. Abuhadra N, Sun R, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Bassett R, Lim B, Thompson AM, Mittendorf E, Adrada BE, Damodaran S, White J, Ravenberg E, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin AA, Valero V, Symmans WF, Tripathy D, Moulder S, Huo L. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel). 2022 Mar 04; 14(5). PMID: 35267631; PMCID: PMC8909018.
      Citations:    
    73. Tarantino P, Corti C, Schmid P, Cortes J, Mittendorf EA, Rugo H, Tolaney SM, Bianchini G, Curigliano G, Andr? F. Immunotherapy for early triple negative breast cancer: research agenda for the next decade. NPJ Breast Cancer. 2022 Feb 18; 8(1):23. PMID: 35181659; PMCID: PMC8857212.
      Citations: 1     
    74. Jimenez JE, Abdelhafez A, Mittendorf EA, Elshafeey N, Yung JP, Litton JK, Adrada BE, Candelaria RP, White J, Thompson AM, Huo L, Wei P, Tripathy D, Valero V, Yam C, Hazle JD, Moulder SL, Yang WT, Rauch GM. A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. Eur J Radiol. 2022 Apr; 149:110220. PMID: 35193025.
      Citations: 1     Fields:    Translation:HumansCells
    75. Weiss A, King C, Grossmith S, Portnow L, Raza S, Nakhlis F, Dominici L, Barbie T, Minami C, Nimbkar S, Rhei E, Mittendorf EA, King TA. How Often Does Retrieval of a Clipped Lymph Node Change Adjuvant Therapy Recommendations? A Prospective, Consecutive, Patient Cohort Study. Ann Surg Oncol. 2022 Jun; 29(6):3764-3771. PMID: 35041097.
      Citations:    Fields:    Translation:Humans
    76. Tarantino P, Garrido-Castro AC, McAllister SS, Guerriero JL, Mittendorf E, Curigliano G, Tolaney SM, Barroso-Sousa R. Understanding resistance to immune checkpoint inhibitors in advanced breast cancer. Expert Rev Anticancer Ther. 2022 Feb; 22(2):141-153. PMID: 34919490.
      Citations:    Fields:    Translation:Humans
    77. Kantor O, King TA, Shak S, Russell CA, Giuliano AE, Hortobagyi GN, Burstein HJ, Winer EP, Dey T, Sparano JA, Mittendorf EA. Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer. J Natl Cancer Inst. 2021 11 29; 113(12):1744-1750. PMID: 34010423; PMCID: PMC8634483.
      Citations: 1     Fields:    
    78. Butner JD, Martin GV, Wang Z, Corradetti B, Ferrari M, Esnaola N, Chung C, Hong DS, Welsh JW, Hasegawa N, Mittendorf EA, Curley SA, Chen SH, Pan PY, Libutti SK, Ganesan S, Sidman RL, Pasqualini R, Arap W, Koay EJ, Cristini V. Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling. Elife. 2021 11 09; 10. PMID: 34749885; PMCID: PMC8629426.
      Citations:    Fields:    Translation:Humans
    79. Sella T, Weiss A, Mittendorf EA, King TA, Pilewskie M, Giuliano AE, Metzger-Filho O. Neoadjuvant Endocrine Therapy in Clinical Practice: A Review. JAMA Oncol. 2021 Nov 01; 7(11):1700-1708. PMID: 34499101.
      Citations: 3     Fields:    Translation:Humans
    80. Yam C, Yen EY, Chang JT, Bassett RL, Alatrash G, Garber H, Huo L, Yang F, Philips AV, Ding QQ, Lim B, Ueno NT, Kannan K, Sun X, Sun B, Parra Cuentas ER, Symmans WF, White JB, Ravenberg E, Seth S, Guerriero JL, Rauch GM, Damodaran S, Litton JK, Wargo JA, Hortobagyi GN, Futreal A, Wistuba II, Sun R, Moulder SL, Mittendorf EA. Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clin Cancer Res. 2021 10 01; 27(19):5365-5375. PMID: 34253579; PMCID: PMC8752638.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    81. Keenan TE, Guerriero JL, Barroso-Sousa R, Li T, O'Meara T, Giobbie-Hurder A, Tayob N, Hu J, Severgnini M, Agudo J, Vaz-Luis I, Anderson L, Attaya V, Park J, Conway J, He MX, Reardon B, Shannon E, Wulf G, Spring LM, Jeselsohn R, Krop I, Lin NU, Partridge A, Winer EP, Mittendorf EA, Liu D, Van Allen EM, Tolaney SM. Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nat Commun. 2021 09 21; 12(1):5563. PMID: 34548479; PMCID: PMC8455578.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    82. Bergholtz H, Carter JM, Cesano A, Cheang MCU, Goel S, Guerriero JL, Hwang ES, Kuasne H, Lee J, Mittendorf EA, Prat A, Pusztai L, Riazalhosseini Y, Richer JK, Schlam I, Stover DG, Swain SM, Swarbrick A, Thompson EA, Tolaney SM, Church SE, Divakar P, Fuhrman CA, Gong J, Hoang ML, Liang Y, Perez J, Reeves JW, Sahin ?, Sato H, S?rlie T, Warren SE. Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx? Digital Spatial Profiler. Cancers (Basel). 2021 Sep 04; 13(17). PMID: 34503266; PMCID: PMC8431590.
      Citations: 6     
    83. Kantor O, Means J, Grossmith S, Dey T, Bellon JR, Mittendorf EA, King TA. Optimizing Axillary Management in Clinical T1-2N0 Mastectomy Patients with Positive Sentinel Lymph Nodes. Ann Surg Oncol. 2022 Feb; 29(2):972-980. PMID: 34467507.
      Citations: 2     Fields:    Translation:Humans
    84. Barroso-Sousa R, Keenan TE, Li T, Tayob N, Trippa L, Pastorello RG, Richardson Iii ET, Dillon D, Amoozgar Z, Overmoyer B, Schnitt SJ, Winer EP, Mittendorf EA, Van Allen E, Duda DG, Tolaney SM. Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. NPJ Breast Cancer. 2021 Aug 25; 7(1):110. PMID: 34433812; PMCID: PMC8387440.
      Citations: 1     
    85. Kantor O, Mittendorf EA. ASO Author Reflections: Racial and Socioeconomic Disparities in Breast Cancer Mortality Persist Beyond Tumor Biology. Ann Surg Oncol. 2022 01; 29(1):697-698. PMID: 34403007.
      Citations:    Fields:    Translation:Humans
    86. Lal JC, Townsend MG, Mehta AK, Oliwa M, Miller E, Sotayo A, Cheney E, Mittendorf EA, Letai A, Guerriero JL. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer. Breast Cancer Res. 2021 08 05; 23(1):83. PMID: 34353349; PMCID: PMC8340363.
      Citations: 1     Fields:    Translation:AnimalsCells
    87. Emens LA, Adams S, Cimino-Mathews A, Disis ML, Gatti-Mays ME, Ho AY, Kalinsky K, McArthur HL, Mittendorf EA, Nanda R, Page DB, Rugo HS, Rubin KM, Soliman H, Spears PA, Tolaney SM, Litton JK. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. J Immunother Cancer. 2021 08; 9(8). PMID: 34389617; PMCID: PMC8365813.
      Citations: 14     Fields:    Translation:Humans
    88. Kantor O, Wang ML, Bertrand K, Pierce L, Freedman RA, Chavez-MacGregor M, King TA, Mittendorf EA. Racial and Socioeconomic Disparities in Breast Cancer Outcomes within the AJCC Pathologic Prognostic Staging System. Ann Surg Oncol. 2022 Jan; 29(1):686-696. PMID: 34331158.
      Citations: 1     Fields:    Translation:Humans
    89. Goldberg J, Pastorello RG, Vallius T, Davis J, Cui YX, Agudo J, Waks AG, Keenan T, McAllister SS, Tolaney SM, Mittendorf EA, Guerriero JL. The Immunology of Hormone Receptor Positive Breast Cancer. Front Immunol. 2021; 12:674192. PMID: 34135901; PMCID: PMC8202289.
      Citations: 9     Fields:    Translation:HumansCells
    90. Kantor O, Laws A, Pastorello RG, King C, Wong S, Dey T, Schnitt S, King TA, Mittendorf EA. Comparison of Breast Cancer Staging Systems After Neoadjuvant Chemotherapy. Ann Surg Oncol. 2021 Nov; 28(12):7347-7355. PMID: 33956276.
      Citations: 2     Fields:    Translation:Humans
    91. Mai J, Li Z, Xia X, Zhang J, Li J, Liu H, Shen J, Ramirez M, Li F, Li Z, Yokoi K, Liu X, Mittendorf EA, Ferrari M, Shen H. Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine. Adv Sci (Weinh). 2021 06; 8(12):2100166. PMID: 34194942; PMCID: PMC8224417.
      Citations: 3     Fields:    Translation:AnimalsCells
    92. Laws A, Garrido-Castro A, Poorvu P, Winer E, Mittendorf E, King T. Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer. Oncology (Williston Park). 2021 Feb 11; 35(2):77-84. PMID: 33577165.
      Citations: 3     Fields:    Translation:Humans
    93. Chick RC, Clifton GT, Hale DF, Vreeland TJ, Hickerson AT, Kemp Bohan PM, McCarthy PM, Litton JK, Alatrash G, Murthy RK, Qiao N, Philips A, Lukas J, Holmes JP, Mittendorf EA, Peoples GE. Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer. Clin Immunol. 2021 04; 225:108679. PMID: 33485895.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    94. Simons JM, Scoggins ME, Kuerer HM, Krishnamurthy S, Yang WT, Sahin AA, Shen Y, Lin H, Bedrosian I, Mittendorf EA, Thompson A, Lane DL, Hunt KK, Caudle AS. Prospective Registry Trial Assessing the Use of Magnetic Seeds to Locate Clipped Nodes After Neoadjuvant Chemotherapy for Breast Cancer Patients. Ann Surg Oncol. 2021 Aug; 28(8):4277-4283. PMID: 33417121.
      Citations: 4     Fields:    Translation:Humans
    95. Bagati A, Kumar S, Jiang P, Pyrdol J, Zou AE, Godicelj A, Mathewson ND, Cartwright ANR, Cejas P, Brown M, Giobbie-Hurder A, Dillon D, Agudo J, Mittendorf EA, Liu XS, Wucherpfennig KW. Integrin av?6-TGF?-SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer. Cancer Cell. 2021 01 11; 39(1):54-67.e9. PMID: 33385331; PMCID: PMC7855651.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    96. Y?lamos J, Mehta AK, Cheney EM, Hartl CA, Pantelidou C, Oliwa M, Castrillon JA, Lin JR, Hurst KE, de Oliveira Taveira M, Johnson NT, Oldham WM, Kalocsay M, Berberich MJ, Boswell SA, Kothari A, Johnson S, Dillon DA, Lipschitz M, Rodig S, Santagata S, Garber JE, Tung N, Thaxton JE, Mittendorf EA, Sorger PK, Shapiro GI, Guerriero JL. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nat Cancer. 2021 01; 2(1):66-82. PMID: 33738458; PMCID: PMC7963404.
      Citations: 33     Translation:HumansCells
    97. Singh P, Scoggins ME, Sahin AA, Hwang RF, Kuerer HM, Caudle AS, Mittendorf EA, Thompson AM, Bedrosian I, Teshome M, DeSnyder SM, Meric-Bernstam F, Hunt KK. Effectiveness and Safety of Magseed-localization for Excision of Breast Lesions: A Prospective, Phase IV Trial. Ann Surg Open. 2020 Dec; 1(2). PMID: 34017965; PMCID: PMC8130552.
      Citations: 1     
    98. Alvarado MD, Mittendorf EA, Teshome M, Thompson AM, Bold RJ, Gittleman MA, Beitsch PD, Blair SL, Kivilaid K, Harmer QJ, Hunt KK. Correction to: SentimagIC: A Non-inferiority Trial Comparing Superparamagnetic Iron Oxide Versus Technetium-99m and Blue Dye in the Detection of Axillary Sentinel Nodes in Patients with Early-Stage Breast Cancer. Ann Surg Oncol. 2020 Dec; 27(Suppl 3):979. PMID: 32514803.
      Citations:    Fields:    
    99. Keenan TE, Li T, Vallius T, Guerriero JL, Tayob N, Kochupurakkal B, Davis J, Pastorello R, Tahara RK, Anderson L, Conway J, He MX, Shannon E, Godin RE, Sorger PK, D'Andrea A, Overmoyer B, Winer EP, Mittendorf EA, Van Allen EM, Shapiro GI, Tolaney SM. Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2021 02 15; 27(4):983-991. PMID: 33257427; PMCID: PMC7887044.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    100. Pastorello RG, Laws A, Grossmith S, King C, McGrath M, Mittendorf EA, King TA, Schnitt SJ. Clinico-pathologic predictors of patterns of residual disease following neoadjuvant chemotherapy for breast cancer. Mod Pathol. 2021 05; 34(5):875-882. PMID: 33219297.
      Citations: 2     Fields:    Translation:Humans
    101. Bradley SD, Talukder AH, Lai I, Davis R, Alvarez H, Tiriac H, Zhang M, Chiu Y, Melendez B, Jackson KR, Katailiha A, Sonnemann HM, Li F, Kang Y, Qiao N, Pan BF, Lorenzi PL, Hurd M, Mittendorf EA, Peterson CB, Javle M, Bristow C, Kim M, Tuveson DA, Hawke D, Kopetz S, Wolff RA, Hwu P, Maitra A, Roszik J, Yee C, Liz?e G. Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. Nat Commun. 2020 10 21; 11(1):5332. PMID: 33087697; PMCID: PMC7577998.
      Citations: 5     Fields:    Translation:HumansCells
    102. Weiss A, Mittendorf EA, King TA. Strategies to Optimize Axillary Surgery in Patients With Breast Cancer Receiving Neoadjuvant Endocrine Therapy. Oncology (Williston Park). 2020 Oct 09; 34(10):397-404. PMID: 33058105.
      Citations:    Fields:    Translation:Humans
    103. Tolaney SM, Barroso-Sousa R, Keenan T, Li T, Trippa L, Vaz-Luis I, Wulf G, Spring L, Sinclair NF, Andrews C, Pittenger J, Richardson ET, Dillon D, Lin NU, Overmoyer B, Partridge AH, Van Allen E, Mittendorf EA, Winer EP, Krop IE. Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2020 10 01; 6(10):1598-1605. PMID: 32880602; PMCID: PMC7489368.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    104. Bellon JR, Burstein HJ, Frank ES, Mittendorf EA, King TA. Multidisciplinary considerations in the treatment of triple-negative breast cancer. CA Cancer J Clin. 2020 11; 70(6):432-442. PMID: 32986241.
      Citations: 2     Fields:    Translation:Humans
    105. Mittendorf EA, Zhang H, Saji S, Jung KH, Sohn J, Iwata H, Telli ML, Punie K, Patel S, Duc AN, Liste-Hermoso M, Maiya V, Molinero L, Chui SY, Harbeck N, Barrios CH, Hegg R, Koehler A, Ferrario C, Penault-Llorca F. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020 10 10; 396(10257):1090-1100. PMID: 32966830.
      Citations: 147     Fields:    Translation:HumansCTClinical Trials
    106. Losk K, Freedman RA, Laws A, Kantor O, Mittendorf EA, Tan-Wasielewski Z, Trippa L, Lin NU, Winer EP, King TA. Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center. Breast Cancer Res Treat. 2021 Jan; 185(1):215-227. PMID: 32939592.
      Citations: 5     Fields:    Translation:Humans
    107. Kantor O, Wakeman M, Weiss A, Wong S, Laws A, Grossmith S, Mittendorf EA, King TA. Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer. Ann Surg Oncol. 2021 Mar; 28(3):1358-1367. PMID: 32869154.
      Citations: 6     Fields:    Translation:Humans
    108. Kantor O, Wong S, Weiss A, Metzger O, Mittendorf EA, King TA. Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer. NPJ Breast Cancer. 2020; 6:35. PMID: 32821803; PMCID: PMC7426953.
      Citations: 8     
    109. Minami CA, Kantor O, Weiss A, Nakhlis F, King TA, Mittendorf EA. Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer. J Am Coll Surg. 2020 10; 231(4):434-447.e2. PMID: 32771654; PMCID: PMC7409804.
      Citations: 11     Fields:    Translation:HumansCellsPHPublic Health
    110. Minami CA, King TA, Mittendorf EA. Patient preferences for locoregional therapy in early-stage breast cancer. Breast Cancer Res Treat. 2020 Sep; 183(2):291-309. PMID: 32691377.
      Citations: 1     Fields:    Translation:Humans
    111. Weiss A, King TA, Mittendorf EA. The Landmark Series: Neoadjuvant Endocrine Therapy for Breast Cancer. Ann Surg Oncol. 2020 Sep; 27(9):3393-3401. PMID: 32591951.
      Citations: 2     Fields:    Translation:Humans
    112. Smith BD, Mittendorf EA, Haffty BG. Multidisciplinary Locoregional Management of Breast Cancer. J Clin Oncol. 2020 07 10; 38(20):2217-2219. PMID: 32442061.
      Citations:    Fields:    Translation:Humans
    113. Mittendorf EA, Bellon JR, King TA. Regional Nodal Management in Patients With Clinically Node-Negative Breast Cancer Undergoing Upfront Surgery. J Clin Oncol. 2020 07 10; 38(20):2273-2280. PMID: 32442075.
      Citations:    Fields:    Translation:Humans
    114. Ho AY, Wright JL, Blitzblau RC, Mutter RW, Duda DG, Norton L, Bardia A, Spring L, Isakoff SJ, Chen JH, Grassberger C, Bellon JR, Beriwal S, Khan AJ, Speers C, Dunn SA, Thompson A, Santa-Maria CA, Krop IE, Mittendorf E, King TA, Gupta GP. Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):227-241. PMID: 32417409; PMCID: PMC7646202.
      Citations: 6     Fields:    Translation:Humans
    115. Brown TA, Mittendorf EA, Hale DF, Myers JW, Peace KM, Jackson DO, Greene JM, Vreeland TJ, Clifton GT, Ardavanis A, Litton JK, Shumway NM, Symanowski J, Murray JL, Ponniah S, Anastasopoulou EA, Pistamaltzian NF, Baxevanis CN, Perez SA, Papamichail M, Peoples GE. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence. Breast Cancer Res Treat. 2020 Jun; 181(2):391-401. PMID: 32323103; PMCID: PMC7188712.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    116. Clifton GT, Hale D, Vreeland TJ, Hickerson AT, Litton JK, Alatrash G, Murthy RK, Qiao N, Philips AV, Lukas JJ, Holmes JP, Peoples GE, Mittendorf EA. Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer. Clin Cancer Res. 2020 06 01; 26(11):2515-2523. PMID: 32071118; PMCID: PMC8771534.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    117. Barroso-Sousa R, Keenan TE, Pernas S, Exman P, Jain E, Garrido-Castro AC, Hughes M, Bychkovsky B, Umeton R, Files JL, Lindeman NI, MacConaill LE, Hodi FS, Krop IE, Dillon D, Winer EP, Wagle N, Lin NU, Mittendorf EA, Van Allen EM, Tolaney SM. Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2020 06 01; 26(11):2565-2572. PMID: 32019858; PMCID: PMC7269810.
      Citations: 51     Fields:    Translation:Humans
    118. Krop IE, Trippa L, Tan-Wasielewski Z, Li T, Osmani W, Andrews C, Dillon D, Richardson ET, Pastorello RG, Winer EP, Mittendorf EA, Bellon JR, Schoenfeld JD, Tolaney SM, Barroso-Sousa R. A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer. Clin Breast Cancer. 2020 06; 20(3):238-245. PMID: 32113750.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    119. Kantor O, Niu J, Zhao H, Giordano SH, Hunt KK, King TA, Mittendorf EA, Chavez-MacGregor M. Comparative Analysis of Proposed Strategies for Incorporating Biologic Factors into Breast Cancer Staging. Ann Surg Oncol. 2020 Jul; 27(7):2229-2237. PMID: 31916091.
      Citations: 4     Fields:    Translation:Humans
    120. Lagendijk M, Mittendorf E, King TA, Gibbons C, Pusic A, Dominici LS. Incorporating Patient-Reported Outcome Measures into Breast Surgical Oncology: Advancing Toward Value-Based Care. Oncologist. 2020 05; 25(5):384-390. PMID: 31848315; PMCID: PMC7216450.
      Citations: 1     Fields:    Translation:Humans
    121. Adams S, Mittendorf EA. Lack of Robust Prognostic Biomarkers for Immunotherapy in Breast Cancer-Adverse Events-In Reply. JAMA Oncol. 2019 Nov 01; 5(11):1640. PMID: 31513254.
      Citations: 5     Fields:    
    122. Yi M, Lin H, Bedrosian I, Shen Y, Hunt KK, Chavez-MacGregor M, King TA, Mittendorf EA. Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors. Ann Surg Oncol. 2020 Feb; 27(2):359-366. PMID: 31667721.
      Citations:    Fields:    Translation:Humans
    123. Gatti-Mays ME, Balko JM, Gameiro SR, Bear HD, Prabhakaran S, Fukui J, Disis ML, Nanda R, Gulley JL, Kalinsky K, Abdul Sater H, Sparano JA, Cescon D, Page DB, McArthur H, Adams S, Mittendorf EA. If we build it they will come: targeting the immune response to breast cancer. NPJ Breast Cancer. 2019; 5:37. PMID: 31700993; PMCID: PMC6820540.
      Citations: 58     
    124. Page DB, Bear H, Prabhakaran S, Gatti-Mays ME, Thomas A, Cobain E, McArthur H, Balko JM, Gameiro SR, Nanda R, Gulley JL, Kalinsky K, White J, Litton J, Chmura SJ, Polley MY, Vincent B, Cescon DW, Disis ML, Sparano JA, Mittendorf EA, Adams S. Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. NPJ Breast Cancer. 2019; 5:34. PMID: 31602395; PMCID: PMC6783471.
      Citations: 22     
    125. Weiss A, Wong S, Golshan M, Freedman RA, Metzger O, Bellon J, Mittendorf EA, King TA. Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach. Ann Surg Oncol. 2019 Dec; 26(13):4326-4336. PMID: 31562601.
      Citations: 8     Fields:    Translation:Humans
    126. Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worms H, Moulder SL, Arun BK. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol. 2020 02 10; 38(5):388-394. PMID: 31461380; PMCID: PMC7351336.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    127. Iorgulescu JB, Freedman RA, Lester SC, Mittendorf EA, Brock JE. 21-Gene Recurrence Score Adds Significant Value for Grade 3 Breast Cancers: Results From a National Cohort. JCO Precis Oncol. 2019; 3. PMID: 32457931; PMCID: PMC7250459.
      Citations: 1     Fields:    
    128. Adams S, Gatti-Mays ME, Kalinsky K, Korde LA, Sharon E, Amiri-Kordestani L, Bear H, McArthur HL, Frank E, Perlmutter J, Page DB, Vincent B, Hayes JF, Gulley JL, Litton JK, Hortobagyi GN, Chia S, Krop I, White J, Sparano J, Disis ML, Mittendorf EA. Current Landscape of Immunotherapy in Breast Cancer: A Review. JAMA Oncol. 2019 Aug 01; 5(8):1205-1214. PMID: 30973611; PMCID: PMC8452050.
      Citations: 80     Fields:    
    129. Hartl CA, Bertschi A, Puerto RB, Andresen C, Cheney EM, Mittendorf EA, Guerriero JL, Goldberg MS. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer. J Immunother Cancer. 2019 07 30; 7(1):199. PMID: 31362778; PMCID: PMC6668091.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    130. Wong SM, Weiss A, Mittendorf EA, King TA, Golshan M. Surgical Management of the Axilla in Clinically Node-Positive Patients Receiving Neoadjuvant Chemotherapy: A National Cancer Database Analysis. Ann Surg Oncol. 2019 Oct; 26(11):3517-3525. PMID: 31342389.
      Citations: 8     Fields:    Translation:Humans
    131. Alvarado MD, Mittendorf EA, Teshome M, Thompson AM, Bold RJ, Gittleman MA, Beitsch PD, Blair SL, Kivilaid K, Harmer QJ, Hunt KK. SentimagIC: A Non-inferiority Trial Comparing Superparamagnetic Iron Oxide Versus Technetium-99m and Blue Dye in the Detection of Axillary Sentinel Nodes in Patients with Early-Stage Breast Cancer. Ann Surg Oncol. 2019 Oct; 26(11):3510-3516. PMID: 31297674.
      Citations: 11     Fields:    Translation:Humans
    132. Wong SM, Almana N, Choi J, Hu J, Gagnon H, Natsuhara K, Shen AH, DeSantis S, Dominici L, Golshan M, Weiss A, Bellon J, Mittendorf EA, King TA. Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer. Ann Surg Oncol. 2019 Oct; 26(11):3502-3509. PMID: 31228134.
      Citations: 13     Fields:    Translation:HumansCells
    133. Sceneay J, Goreczny GJ, Wilson K, Morrow S, DeCristo MJ, Ubellacker JM, Qin Y, Laszewski T, Stover DG, Barrera V, Hutchinson JN, Freedman RA, Mittendorf EA, McAllister SS. Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer. Cancer Discov. 2019 09; 9(9):1208-1227. PMID: 31217296; PMCID: PMC11167954.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    134. Waks AG, Stover DG, Guerriero JL, Dillon D, Barry WT, Gjini E, Hartl C, Lo W, Savoie J, Brock J, Wesolowski R, Li Z, Damicis A, Philips AV, Wu Y, Yang F, Sullivan A, Danaher P, Brauer HA, Osmani W, Lipschitz M, Hoadley KA, Goldberg M, Perou CM, Rodig S, Winer EP, Krop IE, Mittendorf EA, Tolaney SM. The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy. Clin Cancer Res. 2019 08 01; 25(15):4644-4655. PMID: 31061067; PMCID: PMC6677598.
      Citations: 32     Fields:    Translation:HumansCells
    135. Reddy SM, Reuben A, Barua S, Jiang H, Zhang S, Wang L, Gopalakrishnan V, Hudgens CW, Tetzlaff MT, Reuben JM, Tsujikawa T, Coussens LM, Wani K, He Y, Villareal L, Wood A, Rao A, Woodward WA, Ueno NT, Krishnamurthy S, Wargo JA, Mittendorf EA. Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. Cancer Immunol Res. 2019 06; 7(6):1025-1035. PMID: 31043414; PMCID: PMC7053657.
      Citations: 28     Fields:    Translation:HumansCells
    136. Mittendorf EA, Lu B, Melisko M, Price Hiller J, Bondarenko I, Brunt AM, Sergii G, Petrakova K, Peoples GE. Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial. Clin Cancer Res. 2019 07 15; 25(14):4248-4254. PMID: 31036542.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    137. Weiss A, Lin H, Babiera GV, Bedrosian I, Shaitelman SF, Shen Y, Kuerer HM, Mittendorf EA, Caudle AS, Hunt KK, Hwang RF. Evolution in practice patterns of axillary management following mastectomy in patients with 1-2 positive sentinel nodes. Breast Cancer Res Treat. 2019 Jul; 176(2):435-444. PMID: 31025270.
      Citations: 3     Fields:    Translation:Humans
    138. Zhang J, Mai J, Li F, Shen J, Zhang G, Li J, Hinkle LE, Lin D, Liu X, Li Z, Wang RF, Mittendorf EA, Ferrari M, Shen H. Investigation of parameters that determine Nano-DC vaccine transport. Biomed Microdevices. 2019 04 04; 21(2):39. PMID: 30949852; PMCID: PMC6686196.
      Citations: 1     Fields:    Translation:AnimalsCells
    139. Christopherson K, Lei X, Barcenas C, Buchholz TA, Garg N, Hoffman KE, Kuerer HM, Mittendorf E, Perkins G, Shaitelman SF, Smith GL, Stauder M, Strom EA, Tereffe W, Woodward WA, Smith BD. Outcomes of Curative-Intent Treatment for Patients With Breast Cancer Presenting With Sternal or Mediastinal Involvement. Int J Radiat Oncol Biol Phys. 2019 07 01; 104(3):574-581. PMID: 30851348; PMCID: PMC6548669.
      Citations: 2     Fields:    Translation:Humans
    140. Mittendorf EA, King TA. Routine Use of Oncotype DX Recurrence Score Testing in Node-Positive Hormone Receptor-Positive HER2-Negative Breast Cancer: The Time Has Come. Ann Surg Oncol. 2019 May; 26(5):1173-1175. PMID: 30798446.
      Citations: 5     Fields:    Translation:Humans
    141. Pal SK, Miller MJ, Agarwal N, Chang SM, Chavez-MacGregor M, Cohen E, Cole S, Dale W, Magid Diefenbach CS, Disis ML, Dreicer R, Graham DL, Henry NL, Jones J, Keedy V, Klepin HD, Markham MJ, Mittendorf EA, Rodriguez-Galindo C, Sabel MS, Schilsky RL, Sznol M, Tap WD, Westin SN, Johnson BE. Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2019 04 01; 37(10):834-849. PMID: 30702028.
      Citations: 31     Fields:    Translation:Humans
    142. Alatrash G, Qiao N, Zhang M, Zope M, Perakis AA, Sukhumalchandra P, Philips AV, Garber HR, Kerros C, St John LS, Khouri MR, Khong H, Clise-Dwyer K, Miller LP, Wolpe S, Overwijk WW, Molldrem JJ, Ma Q, Shpall EJ, Mittendorf EA. Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes. Clin Cancer Res. 2019 04 15; 25(8):2610-2620. PMID: 30647079; PMCID: PMC6467811.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    143. Punglia RS, Bifolck K, Golshan M, Lehman C, Collins L, Polyak K, Mittendorf E, Garber J, Hwang SE, Schnitt SJ, Partridge AH, King TA. Epidemiology, Biology, Treatment, and Prevention of Ductal Carcinoma In Situ (DCIS). JNCI Cancer Spectr. 2018 Nov; 2(4):pky063. PMID: 30627695; PMCID: PMC6307658.
      Citations: 6     Fields:    
    144. Caudle AS, Kuerer HM, Krishnamurthy S, Shin K, Hobbs BP, Ma J, Mittendorf EA, Washington AC, DeSnyder SM, Black DM, Hunt KK, Yang WT. Feasibility of fine-needle aspiration for assessing responses to chemotherapy in metastatic nodes marked with clips in breast cancer: A prospective registry study. Cancer. 2019 02 01; 125(3):365-373. PMID: 30359480; PMCID: PMC6340747.
      Citations: 5     Fields:    Translation:Humans
    145. Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, Li CW, Kim T, Chang SS, Lee HH, Hsu JL, Wang HL, Kuo CW, Chang WC, Hadad S, Purdie CA, McCoy AM, Cai S, Tu Y, Litton JK, Mittendorf EA, Moulder SL, Symmans WF, Thompson AM, Piwnica-Worms H, Chen CH, Khoo KH, Hung MC. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Mol Cell. 2018 08 16; 71(4):606-620.e7. PMID: 30118680; PMCID: PMC6786495.
      Citations: 177     Fields:    Translation:HumansAnimalsCells
    146. Jackson DO, Trappey FA, Clifton GT, Vreeland TJ, Peace KM, Hale DF, Litton JK, Murray JL, Perez SA, Papamichail M, Mittendorf EA, Peoples GE. Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design. Clin Immunol. 2018 10; 195:28-35. PMID: 30025819.
      Citations: 5     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    147. Murthy RK, Raghavendra AS, Hess KR, Fujii T, Lim B, Barcenas CH, Zhang H, Chavez-Mac-Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, Ueno NT. Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clin Breast Cancer. 2018 12; 18(6):e1283-e1288. PMID: 30077429.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    148. Armer JM, Ballman KV, McCall L, Armer NC, Sun Y, Udmuangpia T, Hunt KK, Mittendorf EA, Byrd DR, Julian TB, Boughey JC. Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: results of American College of Surgeons Oncology Group (ACOSOG) Z1071 (Alliance) substudy. Support Care Cancer. 2019 Feb; 27(2):495-503. PMID: 29980907; PMCID: PMC6342501.
      Citations: 19     Fields:    Translation:Humans
    149. Stecklein SR, Park M, Liu DD, Valle Goffin JJ, Caudle AS, Mittendorf EA, Barcenas CH, Mougalian S, Woodward WA, Valero V, Sahin AA, Yang WT, Shaitelman SF. Long-Term Impact of Regional Nodal Irradiation in Patients With Node-Positive Breast Cancer Treated With Neoadjuvant Systemic Therapy. Int J Radiat Oncol Biol Phys. 2018 11 01; 102(3):568-577. PMID: 29928946.
      Citations: 2     Fields:    Translation:Humans
    150. Mittendorf EA, Bartlett JMS, Lichtensztajn DL, Chandarlapaty S. Incorporating Biology Into Breast Cancer Staging: American Joint Committee on Cancer, Eighth Edition, Revisions and Beyond. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:38-46. PMID: 30231409.
      Citations: 7     Fields:    Translation:Humans
    151. Weiss A, King TA, Hunt KK, Mittendorf EA. Incorporating Biologic Factors into the American Joint Committee on Cancer Breast Cancer Staging System: Review of the Supporting Evidence. Surg Clin North Am. 2018 Aug; 98(4):687-702. PMID: 30005768.
      Citations: 11     Fields:    Translation:Humans
    152. Valachis A, Mamounas EP, Mittendorf EA, Hayashi N, Ishitobi M, Natoli C, Fitzal F, Rubio IT, Tiezzi DG, Shin HC, Anderson SJ, Hunt KK, Matsuda N, Ohsumi S, Totomi A, Nilsson C. Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis. Cancer. 2018 07 15; 124(14):2923-2930. PMID: 29723396.
      Citations: 7     Fields:    Translation:Humans
    153. Alatrash G, Perakis AA, Kerros C, Peters HL, Sukhumalchandra P, Zhang M, Jakher H, Zope M, Patenia R, Sergeeva A, Yi S, Young KH, Philips AV, Cernosek AM, Garber HR, Qiao N, Weng J, St John LS, Lu S, Clise-Dwyer K, Mittendorf EA, Ma Q, Molldrem JJ. Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma. Clin Cancer Res. 2018 07 15; 24(14):3386-3396. PMID: 29661776.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    154. Vreeland TJ, Litton JK, Qiao N, Philips AV, Alatrash G, Hale DF, Jackson DO, Peace KM, Greene JM, Berry JS, Clifton GT, Peoples GE, Mittendorf EA. Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response. Clin Immunol. 2018 07; 192:6-13. PMID: 29574039; PMCID: PMC5988975.
      Citations: 4     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    155. Weiss A, Chavez-MacGregor M, Lichtensztajn DY, Yi M, Tadros A, Hortobagyi GN, Giordano SH, Hunt KK, Mittendorf EA. Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer. JAMA Oncol. 2018 Feb 01; 4(2):203-209. PMID: 29222540; PMCID: PMC5838705.
      Citations: 60     Fields:    Translation:Humans
    156. Le-Petross HT, McCall LM, Hunt KK, Mittendorf EA, Ahrendt GM, Wilke LG, Ballman KV, Boughey JC. Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance). AJR Am J Roentgenol. 2018 Mar; 210(3):669-676. PMID: 29381381; PMCID: PMC5884109.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    157. Khan M, Carmona S, Sukhumalchandra P, Roszik J, Philips A, Perakis AA, Kerros C, Zhang M, Qiao N, John LSS, Zope M, Goldberg J, Qazilbash M, Jakher H, Clise-Dwyer K, Qiu Y, Mittendorf EA, Molldrem JJ, Kornblau SM, Alatrash G. Cathepsin G Is Expressed by Acute Lymphoblastic Leukemia and Is a Potential Immunotherapeutic Target. Front Immunol. 2017; 8:1975. PMID: 29422892; PMCID: PMC5790053.
      Citations: 9     Fields:    
    158. Plichta JK, Campbell BM, Mittendorf EA, Hwang ES. Anatomy and Breast Cancer Staging: Is It Still Relevant? Surg Oncol Clin N Am. 2018 01; 27(1):51-67. PMID: 29132565.
      Citations: 8     Fields:    Translation:Humans
    159. Chavez-MacGregor M, Mittendorf EA. Extended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questions. Lancet Oncol. 2017 12; 18(12):1568-1569. PMID: 29146400.
      Citations: 1     Fields:    Translation:Humans
    160. Ohri N, Sittig MP, Tsai CJ, Hwang ES, Mittendorf EA, Shi W, Zhang Z, Ho AY. Trends and variations in postmastectomy radiation therapy for breast cancer in patients with 1 to 3 positive lymph nodes: A National Cancer Data Base analysis. Cancer. 2018 02 01; 124(3):482-490. PMID: 29112227.
      Citations: 4     Fields:    Translation:Humans
    161. Weiss A, Mittendorf EA, DeSnyder SM, Hwang RF, Bea V, Bedrosian I, Hoffman K, Adrade B, Sahin AA, Kuerer HM, Hunt KK, Caudle AS. Expanding Implementation of ACOSOG Z0011 in Surgeon Practice. Clin Breast Cancer. 2018 08; 18(4):276-281. PMID: 29100726; PMCID: PMC5899057.
      Citations: 7     Fields:    Translation:Humans
    162. Ballman KV, McCall LM, Mittendorf EA, Symmans WF, Julian TB, Byrd D, Hunt KK, Boughey JC. Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance). Ann Surg. 2017 10; 266(4):667-676. PMID: 28657941; PMCID: PMC5755619.
      Citations: 15     Fields:    Translation:Humans
    163. Shen H, Sun T, Hoang HH, Burchfield JS, Hamilton GF, Mittendorf EA, Ferrari M. Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells. Semin Immunol. 2017 12; 34:114-122. PMID: 28947107; PMCID: PMC5705528.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    164. Gall VA, Philips AV, Qiao N, Clise-Dwyer K, Perakis AA, Zhang M, Clifton GT, Sukhumalchandra P, Ma Q, Reddy SM, Yu D, Molldrem JJ, Peoples GE, Alatrash G, Mittendorf EA. Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells. Cancer Res. 2017 10 01; 77(19):5374-5383. PMID: 28819024; PMCID: PMC5626640.
      Citations: 46     Fields:    Translation:HumansAnimalsCells
    165. Mittendorf EA, Chavez-MacGregor M. All HER2-Positive Tumors are not Created Equal. Ann Surg Oncol. 2017 11; 24(12):3471-3474. PMID: 28815451.
      Citations: 1     Fields:    Translation:Humans
    166. Caudle AS, Bedrosian I, DeSnyder SM, Kuerer HM, Hunt KK, Mittendorf EA, Milton DR. Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members. Ann Surg Oncol. 2017 Oct; 24(10):2925-2934. PMID: 28766207; PMCID: PMC5759951.
      Citations: 15     Fields:    Translation:Humans
    167. Mittendorf EA, Chavez-MacGregor M, Vila J, Yi M, Lichtensztajn DY, Clarke CA, Giordano SH, Hunt KK. Bioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology. Ann Surg Oncol. 2017 Nov; 24(12):3502-3509. PMID: 28726077; PMCID: PMC5880531.
      Citations: 16     Fields:    Translation:Humans
    168. DeSnyder SM, Mittendorf EA, Le-Petross C, Krishnamurthy S, Whitman GJ, Ueno NT, Woodward WA, Kuerer HM, Akay CL, Babiera GV, Yang W, Lucci A. Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast?Cancer. Clin Breast Cancer. 2018 02; 18(1):e73-e77. PMID: 28755879.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    169. Akay CL, Albarracin C, Torstenson T, Bassett R, Mittendorf EA, Yi M, Kuerer HM, Babiera GV, Bedrosian I, Hunt KK, Hwang RF. Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer. Breast J. 2018 01; 24(1):28-34. PMID: 28608612; PMCID: PMC5729065.
      Citations: 12     Fields:    Translation:Humans
    170. Chavez-MacGregor M, Mittendorf EA, Clarke CA, Lichtensztajn DY, Hunt KK, Giordano SH. Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System. Oncologist. 2017 11; 22(11):1292-1300. PMID: 28592619; PMCID: PMC5679819.
      Citations: 31     Fields:    Translation:Humans
    171. Harao M, Roszik J, Gao H, Babiera GV, Krishnamurthy S, Chacon JA, Li S, Mittendorf EA, DeSnyder SM, Rockwood KF, Bernatchez C, Ueno NT, Radvanyi LG, Vence L, Haymaker C, Reuben JM, Forget MA. 4-1BB-Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells. Cancer Immunol Res. 2017 06; 5(6):439-445. PMID: 28473315; PMCID: PMC5525328.
      Citations: 18     Fields:    Translation:HumansCells
    172. Kerros C, Tripathi SC, Zha D, Mehrens JM, Sergeeva A, Philips AV, Qiao N, Peters HL, Katayama H, Sukhumalchandra P, Ruisaard KE, Perakis AA, St John LS, Lu S, Mittendorf EA, Clise-Dwyer K, Herrmann AC, Alatrash G, Toniatti C, Hanash SM, Ma Q, Molldrem JJ. Neuropilin-1 mediates neutrophil elastase uptake and cross-presentation in breast cancer cells. J Biol Chem. 2017 06 16; 292(24):10295-10305. PMID: 28468826; PMCID: PMC5473232.
      Citations: 18     Fields:    Translation:HumansCells
    173. Clifton GT, Litton JK, Arrington K, Ponniah S, Ibrahim NK, Gall V, Alatrash G, Peoples GE, Mittendorf EA. Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+?T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients. Ann Surg Oncol. 2017 Aug; 24(8):2161-2167. PMID: 28315060; PMCID: PMC5908243.
      Citations: 12     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    174. Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ, Hortobagyi GN. Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 07 08; 67(4):290-303. PMID: 28294295.
      Citations: 226     Fields:    Translation:Humans
    175. Teshome M, Tucker SL, Woodward WA, Chavez-MacGregor M, Hunt KK, Mittendorf EA, Vila J. Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer. Ann Surg. 2017 03; 265(3):574-580. PMID: 27735826; PMCID: PMC11023020.
      Citations: 10     Fields:    Translation:Humans
    176. Dominici LS, Morrow M, Mittendorf E, Bellon J, King TA. Trends and controversies in multidisciplinary care of the patient with breast cancer. Curr Probl Surg. 2016 Dec; 53(12):559-595. PMID: 28160790; PMCID: PMC5298793.
      Citations: 3     Fields:    Translation:Humans
    177. Castaneda CA, Mittendorf E, Casavilca S, Wu Y, Castillo M, Arboleda P, Nunez T, Guerra H, Barrionuevo C, Dolores-Cerna K, Belmar-Lopez C, Abugattas J, Calderon G, De La Cruz M, Cotrina M, Dunstan J, Gomez HL, Vidaurre T. Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy. World J Clin Oncol. 2016 Oct 10; 7(5):387-394. PMID: 27777881; PMCID: PMC5056330.
      Citations: 16     
    178. Mittendorf EA, Ardavanis A, Litton JK, Shumway NM, Hale DF, Murray JL, Perez SA, Ponniah S, Baxevanis CN, Papamichail M, Peoples GE. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence. Oncotarget. 2016 Oct 04; 7(40):66192-66201. PMID: 27589688; PMCID: PMC5323226.
      Citations: 35     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    179. FitzSullivan E, Bassett RL, Kuerer HM, Mittendorf EA, Yi M, Hunt KK, Babiera GV, Caudle AS, Black DM, Bedrosian I, Reyna C, Teshome M, Meric-Bernstam F, Hwang R. Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy. Ann Surg Oncol. 2017 Mar; 24(3):652-659. PMID: 27822630; PMCID: PMC5977973.
      Citations: 4     Fields:    Translation:Humans
    180. Alatrash G, Daver N, Mittendorf EA. Targeting Immune Checkpoints in Hematologic Malignancies. Pharmacol Rev. 2016 10; 68(4):1014-1025. PMID: 27664133; PMCID: PMC11060433.
      Citations: 15     Fields:    Translation:Humans
    181. Alatrash G, Garber HR, Zhang M, Sukhumalchandra P, Qiu Y, Jakher H, Perakis AA, Becker L, Yoo SY, Dwyer KC, Coombes K, Talukder AH, John LSS, Senyukov V, Lee DA, Sergeeva A, He H, Ma Q, Armistead PM, Roszik J, Mittendorf EA, Molldrem JJ, Hawke D, Lizee G, Kornblau SM. Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target. Leukemia. 2017 01; 31(1):234-237. PMID: 27573556; PMCID: PMC5215491.
      Citations: 13     Fields:    Translation:HumansAnimals
    182. Carter SA, Lyons GR, Kuerer HM, Bassett RL, Oates S, Thompson A, Caudle AS, Mittendorf EA, Bedrosian I, Lucci A, DeSnyder SM, Babiera G, Yi M, Baumann DP, Clemens MW, Garvey PB, Hunt KK, Hwang RF. Operative and Oncologic Outcomes in 9861 Patients with Operable Breast Cancer: Single-Institution Analysis of Breast Conservation with Oncoplastic Reconstruction. Ann Surg Oncol. 2016 10; 23(10):3190-8. PMID: 27406093.
      Citations: 33     Fields:    Translation:Humans
    183. Mittendorf EA, Vila J, Tucker SL, Chavez-MacGregor M, Smith BD, Symmans WF, Sahin AA, Hortobagyi GN, Hunt KK. The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment. JAMA Oncol. 2016 Jul 01; 2(7):929-36. PMID: 26986538; PMCID: PMC5757376.
      Citations: 34     Fields:    Translation:Humans
    184. Vila J, Mittendorf EA, Farante G, Bassett RL, Veronesi P, Galimberti V, Peradze N, Stauder MC, Chavez-MacGregor M, Litton JF, Huo L, Kuerer HM, Hunt KK, Caudle AS. Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer. Ann Surg Oncol. 2016 10; 23(11):3501-3509. PMID: 27216742.
      Citations: 22     Fields:    Translation:Humans
    185. Mittendorf EA, Peoples GE. Injecting Hope--A Review of Breast Cancer Vaccines. Oncology (Williston Park). 2016 May; 30(5):475-81, 485. PMID: 27188680.
      Citations: 5     Fields:    Translation:HumansAnimals
    186. Chawla A, Alatrash G, Philips AV, Qiao N, Sukhumalchandra P, Kerros C, Diaconu I, Gall V, Neal S, Peters HL, Clise-Dwyer K, Molldrem JJ, Mittendorf EA. Neutrophil elastase enhances antigen presentation by upregulating human leukocyte antigen class I expression on tumor cells. Cancer Immunol Immunother. 2016 06; 65(6):741-51. PMID: 27129972; PMCID: PMC5764112.
      Citations: 10     Fields:    Translation:HumansCells
    187. Clifton GT, Gall V, Peoples GE, Mittendorf EA. Clinical Development of the E75 Vaccine in Breast Cancer. Breast Care (Basel). 2016 Apr; 11(2):116-21. PMID: 27239173; PMCID: PMC4881244.
      Citations: 10     
    188. Knutson KL, Clynes R, Shreeder B, Yeramian P, Kemp KP, Ballman K, Tenner KS, Erskine CL, Norton N, Northfelt D, Tan W, Calfa C, Pegram M, Mittendorf EA, Perez EA. Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain. Cancer Res. 2016 07 01; 76(13):3702-10. PMID: 27197192; PMCID: PMC5594563.
      Citations: 27     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    189. Clifton GT, Peoples GE, Mittendorf EA. The development and use of the E75 (HER2 369-377) peptide vaccine. Future Oncol. 2016 Jun; 12(11):1321-9. PMID: 27044454; PMCID: PMC6040084.
      Citations: 14     Fields:    Translation:HumansAnimals
    190. Ballman KV, Le-Petross HT, McCall LM, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Feliberti EC, Hunt KK, Boughey JC. Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance). Ann Surg. 2016 Apr; 263(4):802-7. PMID: 26649589; PMCID: PMC4777661.
      Citations: 83     Fields:    Translation:HumansCTClinical Trials
    191. Mittendorf EA, Ardavanis A, Symanowski J, Murray JL, Shumway NM, Litton JK, Hale DF, Perez SA, Anastasopoulou EA, Pistamaltzian NF, Ponniah S, Baxevanis CN, von Hofe E, Papamichail M, Peoples GE. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. Ann Oncol. 2016 07; 27(7):1241-8. PMID: 27029708; PMCID: PMC4922316.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    192. Swisher SK, Wu Y, Castaneda CA, Lyons GR, Yang F, Tapia C, Wang X, Casavilca SA, Bassett R, Castillo M, Sahin A, Mittendorf EA. Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group. Ann Surg Oncol. 2016 07; 23(7):2242-8. PMID: 26965699.
      Citations: 32     Fields:    Translation:HumansCells
    193. Tong WMY, Baumann DP, Villa MT, Mittendorf EA, Liu J, Robb GL, Kronowitz SJ, Garvey PB. Obese Women Experience Fewer Complications after Oncoplastic Breast Repair following Partial Mastectomy Than after Immediate Total Breast Reconstruction. Plast Reconstr Surg. 2016 Mar; 137(3):777-791. PMID: 26910658.
      Citations: 8     Fields:    Translation:Humans
    194. Teshome M, Wei C, Hunt KK, Thompson A, Rodriguez K, Mittendorf EA. Use of a Magnetic Tracer for Sentinel Lymph Node Detection in Early-Stage Breast Cancer Patients: A Meta-analysis. Ann Surg Oncol. 2016 May; 23(5):1508-14. PMID: 26893221.
      Citations: 18     Fields:    Translation:Humans
    195. Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, Bedrosian I, Hobbs BP, DeSnyder SM, Hwang RF, Adrada BE, Shaitelman SF, Chavez-MacGregor M, Smith BD, Candelaria RP, Babiera GV, Dogan BE, Santiago L, Hunt KK, Kuerer HM. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol. 2016 Apr 01; 34(10):1072-8. PMID: 26811528; PMCID: PMC4933133.
      Citations: 138     Fields:    Translation:Humans
    196. Sanford RA, Lei X, Barcenas CH, Mittendorf EA, Caudle AS, Valero V, Tripathy D, Giordano SH, Chavez-MacGregor M. Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients. Ann Surg Oncol. 2016 May; 23(5):1515-21. PMID: 26678405.
      Citations: 23     Fields:    Translation:Humans
    197. Clifton GT, Mittendorf EA, Peoples GE. Adjuvant HER2/neu peptide cancer vaccines in breast cancer. Immunotherapy. 2015; 7(11):1159-68. PMID: 26567563.
      Citations: 19     Fields:    Translation:HumansAnimals
    198. Swisher SK, Vila J, Tucker SL, Bedrosian I, Shaitelman SF, Litton JK, Smith BD, Caudle AS, Kuerer HM, Mittendorf EA. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy. Ann Surg Oncol. 2016 Mar; 23(3):749-56. PMID: 26511263.
      Citations: 26     Fields:    Translation:Humans
    199. Knutson KL, Mittendorf EA. Cancer vaccines in the new era of cancer immunotherapy. Vaccine. 2015 Dec 16; 33(51):7376. PMID: 26432907.
      Citations: 2     Fields:    Translation:Humans
    200. McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, Eterovic AK, Sangai T, Holder AM, Sharma C, Chen H, Do KA, Tarco E, Gagea M, Naff KA, Sahin A, Multani AS, Black DM, Mittendorf EA, Bedrosian I, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One. 2015; 10(9):e0136851. PMID: 26325287; PMCID: PMC4556673.
      Citations: 32     Fields:    Translation:HumansAnimals
    201. Mittendorf EA, Bedrosian I, Hunt KK. Reply to L. Antolini et al. J Clin Oncol. 2015 Nov 20; 33(33):3978-9. PMID: 26282647.
      Citations:    Fields:    Translation:Humans
    202. Chaudry M, Lei X, Gonzalez-Angulo AM, Mittendorf EA, Valero V, Tripathy D, Hortobagyi GN, Chavez-MacGregor M. Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2015 Sep; 153(2):417-23. PMID: 26272743.
      Citations: 8     Fields:    Translation:Humans
    203. Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Fraga MF, Piwnica-Worms D, Kalluri R, Weitz J, Rahbari N, Reissfelder C, Pilarsky C. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015 Jul 09; 523(7559):177-82. PMID: 26106858; PMCID: PMC4825698.
      Citations: 969     Fields:    Translation:HumansAnimalsCells
    204. Buchholz TA, Mittendorf EA, Hunt KK. Surgical Considerations After Neoadjuvant Chemotherapy: Breast Conservation Therapy. J Natl Cancer Inst Monogr. 2015 May; 2015(51):11-4. PMID: 26063878; PMCID: PMC6281279.
      Citations: 10     Fields:    Translation:Humans
    205. Francis AM, Haugen CE, Grimes LM, Crow JR, Yi M, Mittendorf EA, Bedrosian I, Caudle AS, Babiera GV, Krishnamurthy S, Kuerer HM, Hunt KK. Is Sentinel Lymph Node Dissection Warranted for Patients with a Diagnosis of Ductal Carcinoma In Situ? Ann Surg Oncol. 2015 Dec; 22(13):4270-9. PMID: 25905585; PMCID: PMC5271669.
      Citations: 15     Fields:    Translation:Humans
    206. Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Flippo-Morton TS, Kuerer HM, Bowling M, Hunt KK, Alliance for Clinical Trials in Oncology, Boughey JC. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). Ann Surg. 2015 Mar; 261(3):547-52. PMID: 25664534; PMCID: PMC4324533.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    207. Smyth MJ, Drake CG, Abastado JP, Apte RN, Blay JY, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Gabrilovich DI, Gilboa E, Gnjatic S, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, van der Burg SH, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC, Apetoh L, Ayyoub M, Bonneville M, Comin-Anduix B, Fridman WH, J?ger D, Tartour E, Valmori D, van der Bruggen P, van den Eynde BJ. Consensus nomenclature for CD8+ T cell phenotypes in cancer. Oncoimmunology. 2015 Apr; 4(4):e998538. PMID: 26137416; PMCID: PMC4485711.
      Citations: 70     Fields:    
    208. Callender GG, Kaplan BJ, White RL, Brenin DR, Chagpar AB, Dalal KM, Howard-McNatt M, Howe J, Kim J, Kurtzman SH, Mansour JC, Mittendorf EA, Stewart JH, Temple LK, Stella P, Cummings C, Wong SL, Klimberg VS. Maintenance of certification: what everyone needs to know. Ann Surg Oncol. 2015 Apr; 22(4):1051-4. PMID: 25663592.
      Citations:    Fields:    Translation:Humans
    209. Boughey JC, Ballman KV, Hunt KK, McCall LM, Mittendorf EA, Ahrendt GM, Wilke LG, Le-Petross HT. Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance). J Clin Oncol. 2015 Oct 20; 33(30):3386-93. PMID: 25646192; PMCID: PMC4606058.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    210. Caudle AS, Yang WT, Mittendorf EA, Black DM, Hwang R, Hobbs B, Hunt KK, Krishnamurthy S, Kuerer HM. Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial. JAMA Surg. 2015 Feb; 150(2):137-43. PMID: 25517573; PMCID: PMC4508192.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    211. Harao M, Mittendorf EA, Radvanyi LG. Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer. BioDrugs. 2015 Feb; 29(1):15-30. PMID: 25523015.
      Citations: 5     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    212. Agostinis P, Apte RN, Beckhove P, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Gabrilovich DI, Garg A, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Kalinski P, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Lotze MT, Lugli E, Mach JP, Mavilio D, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Restifo NP, Rizvi N, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Van Der Burg SH, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zou W, Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqu? A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Aranda F, Ayyoub M, Blay JY, Bracci L, Caignard A, Fridman WH, Fuc?kov? J, Galon J, Ghiringhelli F, Hosmalin A, J?ger D, K?rre K, Kepp O, Liblau R, Mattei F, Melero I, Rabinovich GA, Saut?s-Fridman C, Tartour E, Van Den Eynde BJ, Zitvogel L, Kroemer G. Classification of current anticancer immunotherapies. Oncotarget. 2014 Dec 30; 5(24):12472-508. PMID: 25537519; PMCID: PMC4350348.
      Citations: 164     Fields:    Translation:HumansAnimals
    213. Mittendorf EA, Ballman KV, McCall LM, Yi M, Sahin AA, Bedrosian I, Hansen N, Gabram S, Hurd T, Giuliano AE, Hunt KK. Evaluation of the stage IB designation of the American Joint Committee on Cancer staging system in breast cancer. J Clin Oncol. 2015 Apr 01; 33(10):1119-27. PMID: 25488970; PMCID: PMC4372850.
      Citations: 15     Fields:    Translation:Humans
    214. Ren Y, Black DM, Mittendorf EA, Liu P, Li X, Du XL, He J, Yang J, Hunt KK, Yi M. Crossover effects of estrogen receptor status on breast cancer-specific hazard rates by age and race. PLoS One. 2014; 9(10):e110281. PMID: 25333877; PMCID: PMC4204865.
      Citations: 4     Fields:    Translation:Humans
    215. Parinyanitikul N, Lei X, Chavez-MacGregor M, Liu S, Mittendorf EA, Litton JK, Woodward W, Zhang AH, Hortobagyi GN, Valero V, Meric-Bernstam F, Gonzalez-Angulo AM. Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes. Clin Breast Cancer. 2015 Apr; 15(2):153-60. PMID: 25454687.
      Citations: 16     Fields:    Translation:Humans
    216. McCall LM, Ballman KV, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Flippo-Morton T, Hunt KK, Boughey JC. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg. 2014 Oct; 260(4):608-14; discussion 614-6. PMID: 25203877; PMCID: PMC4159769.
      Citations: 98     Fields:    Translation:HumansCTClinical Trials
    217. Garber HR, Mirza A, Mittendorf EA, Alatrash G. Adoptive T-cell therapy for Leukemia. Mol Cell Ther. 2014; 2:25. PMID: 26056592; PMCID: PMC4452065.
      Citations: 7     
    218. Mittendorf EA, Boughey JC, Hunt KK. SLN surgery for clinically node-positive breast cancer patients treated with neoadjuvant therapy. Bull Am Coll Surg. 2014 Jul; 99(7):52-4. PMID: 25076741.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    219. Meric-Bernstam F, Akcakanat A, Chen H, Sahin A, Tarco E, Carkaci S, Adrada BE, Singh G, Do KA, Garces ZM, Mittendorf E, Babiera G, Bedrosian I, Hwang R, Krishnamurthy S, Symmans WF, Gonzalez-Angulo AM, Mills GB. Influence of biospecimen variables on proteomic biomarkers in breast cancer. Clin Cancer Res. 2014 Jul 15; 20(14):3870-83. PMID: 24895461; PMCID: PMC4112583.
      Citations: 25     Fields:    Translation:HumansCells
    220. Caudle AS, Kuerer HM, Le-Petross HT, Yang W, Yi M, Bedrosian I, Krishnamurthy S, Fornage BD, Hunt KK, Mittendorf EA. Predicting the extent of nodal disease in early-stage breast cancer. Ann Surg Oncol. 2014 Oct; 21(11):3440-7. PMID: 24859939.
      Citations: 30     Fields:    Translation:Humans
    221. Mittendorf EA, Caudle AS, Yang W, Krishnamurthy S, Shaitelman S, Chavez-MacGregor M, Woodward WA, Bedrosian I, Kuerer HM, Hunt KK. Implementation of the american college of surgeons oncology group z1071 trial data in clinical practice: is there a way forward for sentinel lymph node dissection in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy? Ann Surg Oncol. 2014 Aug; 21(8):2468-73. PMID: 24841348.
      Citations: 12     Fields:    Translation:Humans
    222. Mittendorf EA, Hunt KK. Following the data: past, present, and future management of the axilla in breast cancer patients. Oncology (Williston Park). 2014 May; 28(5):378, 380, 382. PMID: 25004649.
      Citations:    Fields:    Translation:Humans
    223. Mittendorf EA, Bedrosian I. Breast cancer biology: implications for local-regional therapy. Ann Surg Oncol. 2014 Sep; 21(9):2820-2. PMID: 24752612.
      Citations:    Fields:    Translation:Humans
    224. Wang J, Mittendorf EA, Sahin AA, Yi M, Caudle A, Hunt KK, Wu Y. Outcomes of sentinel lymph node dissection alone vs. axillary lymph node dissection in early stage invasive lobular carcinoma: a retrospective study of the surveillance, epidemiology and end results (SEER) database. PLoS One. 2014; 9(2):e89778. PMID: 24587029; PMCID: PMC3934955.
      Citations: 14     Fields:    Translation:Humans
    225. Hunt KK, Smith BD, Mittendorf EA. The controversy regarding margin width in breast cancer: enough is enough. Ann Surg Oncol. 2014 Mar; 21(3):701-3. PMID: 24473644.
      Citations: 2     Fields:    Translation:Humans
    226. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014 Apr; 2(4):361-70. PMID: 24764583; PMCID: PMC4000553.
      Citations: 431     Fields:    Translation:HumansCells
    227. Schneble EJ, Berry JS, Trappey FA, Clifton GT, Ponniah S, Mittendorf E, Peoples GE. The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax?) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. Immunotherapy. 2014; 6(5):519-31. PMID: 24896623.
      Citations: 26     Fields:    Translation:Humans
    228. Chawla A, Philips AV, Alatrash G, Mittendorf E. Immune checkpoints: A therapeutic target in triple negative breast cancer. Oncoimmunology. 2014 Jan 01; 3(3):e28325. PMID: 24843833; PMCID: PMC4022604.
      Citations: 15     Fields:    
    229. Meric-Bernstam F, Rasmussen JC, Krishnamurthy S, Tan IC, Zhu B, Wagner JL, Babiera GV, Mittendorf EA, Sevick-Muraca EM. Toward nodal staging of axillary lymph node basins through intradermal administration of fluorescent imaging agents. Biomed Opt Express. 2013 Dec 13; 5(1):183-96. PMID: 24466486; PMCID: PMC3891331.
      Citations: 10     
    230. Shen MC, Massarweh NN, Lari SA, Vaporciyan AA, Selber JC, Mittendorf EA, MacGregor MC, Smith BD, Kuerer HM. Clinical course of breast cancer patients with isolated sternal and full-thickness chest wall recurrences treated with and without radical surgery. Ann Surg Oncol. 2013 Dec; 20(13):4153-60. PMID: 23959054.
      Citations: 3     Fields:    Translation:Humans
    231. McLaughlin S, Mittendorf EA, Bleicher RJ, McCready DR, King TA. The 2013 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: MRI in breast cancer: where are we now? Ann Surg Oncol. 2014 Jan; 21(1):28-36. PMID: 24145992.
      Citations: 4     Fields:    Translation:Humans
    232. Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Kuerer HM, Bowling M, Flippo-Morton TS, Byrd DR, Ollila DW, Julian TB, McLaughlin SA, McCall L, Symmans WF, Le-Petross HT, Haffty BG, Buchholz TA, Nelson H, Hunt KK, Alliance for Clinical Trials in Oncology. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013 Oct 09; 310(14):1455-61. PMID: 24101169; PMCID: PMC4075763.
      Citations: 280     Fields:    Translation:HumansCTClinical Trials
    233. Caudle AS, Yi M, Hoffman KE, Mittendorf EA, Babiera GV, Hwang RF, Meric-Bernstam F, Sahin AA, Hunt KK. Impact of identification of internal mammary sentinel lymph node metastasis in breast cancer patients. Ann Surg Oncol. 2014 Jan; 21(1):60-5. PMID: 24046126.
      Citations: 13     Fields:    Translation:Humans
    234. Fitzsullivan E, Lari SA, Smith B, Caudle AS, Krishnamurthy S, Lucci A, Mittendorf EA, Babiera GV, Black DM, Wagner JL, Bedrosian I, Woodward W, Gainer SM, Hwang R, Meric-Bernstam F, Hunt KK, Kuerer HM. Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? Ann Surg Oncol. 2013 Dec; 20(13):4103-12. PMID: 23975313; PMCID: PMC4337951.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    235. Ibrahim NK, Murray JL, Zhou D, Mittendorf EA, Sample D, Tautchin M, Miles D. Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial. J Cancer. 2013; 4(7):577-84. PMID: 23983823; PMCID: PMC3753533.
      Citations: 35     
    236. Black DM, Hunt KK, Mittendorf EA. Long term outcomes reporting the safety of breast conserving therapy compared to mastectomy: 20-year results of EORTC 10801. Gland Surg. 2013 Aug; 2(3):120-3. PMID: 25083471; PMCID: PMC4115749.
      Citations: 3     
    237. Weksberg DC, Allen PK, Hoffman KE, Litton JK, Strom EA, Shah RR, Kuerer HM, Hunt KK, Buchholz TA, Mittendorf EA. Outcomes and predictive factors for salvage therapy after local--regional recurrence following neoadjuvant chemotherapy and breast conserving therapy. Ann Surg Oncol. 2013 Oct; 20(11):3430-7. PMID: 23720073.
      Citations: 1     Fields:    Translation:Humans
    238. Alatrash G, Jakher H, Stafford PD, Mittendorf EA. Cancer immunotherapies, their safety and toxicity. Expert Opin Drug Saf. 2013 Sep; 12(5):631-45. PMID: 23668362.
      Citations: 55     Fields:    Translation:Humans
    239. Chawla A, Alatrash G, Wu Y, Mittendorf EA. Immune aspects of the breast tumor microenvironment. Breast Cancer Manag. 2013 May 01; 2(3):231-244. PMID: 24516507; PMCID: PMC3917569.
      Citations: 6     
    240. Litton JK, Warneke CL, Hahn KM, Palla SL, Kuerer HM, Perkins GH, Mittendorf EA, Barnett C, Gonzalez-Angulo AM, Theriault RL, Hortob?gyi GN. Case control study of women treated with chemotherapy for breast cancer during pregnancy as compared with nonpregnant patients with breast cancer. Oncologist. 2013; 18(4):369-76. PMID: 23576478; PMCID: PMC3639522.
      Citations: 14     Fields:    Translation:Humans
    241. Mittendorf EA, Buchholz TA, Tucker SL, Meric-Bernstam F, Kuerer HM, Gonzalez-Angulo AM, Bedrosian I, Babiera GV, Hoffman K, Yi M, Ross MI, Hortobagyi GN, Hunt KK. Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy. Ann Surg. 2013 Feb; 257(2):173-9. PMID: 23291658; PMCID: PMC6058313.
      Citations: 28     Fields:    Translation:Humans
    242. Black DM, Mittendorf EA. Landmark trials affecting the surgical management of invasive breast cancer. Surg Clin North Am. 2013 Apr; 93(2):501-18. PMID: 23464699; PMCID: PMC3907110.
      Citations: 15     Fields:    Translation:Humans
    243. Zhang M, Sukhumalchandra P, Enyenihi AA, St John LS, Hunsucker SA, Mittendorf EA, Sergeeva A, Ruisaard K, Al-Atrache Z, Ropp PA, Jakher H, Rodriguez-Cruz T, Lizee G, Clise-Dwyer K, Lu S, Molldrem JJ, Glish GL, Armistead PM, Alatrash G. A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia. Clin Cancer Res. 2013 Jan 01; 19(1):247-57. PMID: 23147993; PMCID: PMC3537920.
      Citations: 14     Fields:    Translation:HumansCells
    244. Yi M, Kuerer HM, Mittendorf EA, Hwang RF, Caudle AS, Bedrosian I, Meric-Bernstam F, Wagner JL, Hunt KK. Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient population. J Am Coll Surg. 2013 Jan; 216(1):105-13. PMID: 23122536; PMCID: PMC4331643.
      Citations: 23     Fields:    Translation:Humans
    245. Alatrash G, Mittendorf EA, Sergeeva A, Sukhumalchandra P, Qiao N, Zhang M, St John LS, Ruisaard K, Haugen CE, Al-Atrache Z, Jakher H, Philips AV, Ding X, Chen JQ, Wu Y, Patenia RS, Bernatchez C, Vence LM, Radvanyi LG, Hwu P, Clise-Dwyer K, Ma Q, Lu S, Molldrem JJ. Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy. J Immunol. 2012 Dec 01; 189(11):5476-84. PMID: 23105141; PMCID: PMC3504175.
      Citations: 18     Fields:    Translation:HumansCells
    246. Song W, Delyria ES, Chen J, Huang W, Lee JS, Mittendorf EA, Ibrahim N, Radvanyi LG, Li Y, Lu H, Xu H, Shi Y, Wang LX, Ross JA, Rodrigues SP, Almeida IC, Yang X, Qu J, Schocker NS, Michael K, Zhou D. MUC1 glycopeptide epitopes predicted by computational glycomics. Int J Oncol. 2012 Dec; 41(6):1977-84. PMID: 23023583; PMCID: PMC3556481.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    247. Hunt KK, Ballman KV, McCall LM, Boughey JC, Mittendorf EA, Cox CE, Whitworth PW, Beitsch PD, Leitch AM, Buchholz TA, Morrow MA, Giuliano AE. Factors associated with local-regional recurrence after a negative sentinel node dissection: results of the ACOSOG Z0010 trial. Ann Surg. 2012 Sep; 256(3):428-36. PMID: 22868365; PMCID: PMC5345746.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    248. Caudle AS, Hunt KK, Tucker SL, Hoffman K, Gainer SM, Lucci A, Kuerer HM, Meric-Bernstam F, Shah R, Babiera GV, Sahin AA, Mittendorf EA. American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns. Ann Surg Oncol. 2012 Oct; 19(10):3144-51. PMID: 22847123; PMCID: PMC4403637.
      Citations: 42     Fields:    Translation:Humans
    249. Gainer SM, Hunt KK, Beitsch P, Caudle AS, Mittendorf EA, Lucci A. Changing behavior in clinical practice in response to the ACOSOG Z0011 trial: a survey of the American Society of Breast Surgeons. Ann Surg Oncol. 2012 Oct; 19(10):3152-8. PMID: 22820938.
      Citations: 25     Fields:    Translation:Humans
    250. Alvarado R, Yi M, Le-Petross H, Gilcrease M, Mittendorf EA, Bedrosian I, Hwang RF, Caudle AS, Babiera GV, Akins JS, Kuerer HM, Hunt KK. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann Surg Oncol. 2012 Oct; 19(10):3177-84. PMID: 22772869.
      Citations: 41     Fields:    Translation:Humans
    251. Hoffman KE, Mittendorf EA, Buchholz TA. Optimising radiation treatment decisions for patients who receive neoadjuvant chemotherapy and mastectomy. Lancet Oncol. 2012 Jun; 13(6):e270-6. PMID: 22652235.
      Citations: 8     Fields:    Translation:Humans
    252. Hale DF, Clifton GT, Sears AK, Vreeland TJ, Shumway N, Peoples GE, Mittendorf EA. Cancer vaccines: should we be targeting patients with less aggressive disease? Expert Rev Vaccines. 2012 Jun; 11(6):721-31. PMID: 22873128.
      Citations: 10     Fields:    Translation:HumansPHPublic Health
    253. Kong AL, Tereffe W, Hunt KK, Yi M, Kang T, Weatherspoon K, Mittendorf EA, Bedrosian I, Hwang RF, Babiera GV, Buchholz TA, Meric-Bernstam F. Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I to III breast cancer. Cancer. 2012 Dec 15; 118(24):6287-96. PMID: 22648744; PMCID: PMC3913471.
      Citations: 9     Fields:    Translation:Humans
    254. Alvarado R, Lari SA, Roses RE, Smith BD, Yang W, Mittendorf EA, Arun BK, Lucci A, Babiera GV, Wagner JL, Caudle AS, Meric-Bernstam F, Hwang RF, Bedrosian I, Hunt KK, Kuerer HM. Biology, treatment, and outcome in very young and older women with DCIS. Ann Surg Oncol. 2012 Nov; 19(12):3777-84. PMID: 22622473; PMCID: PMC3854959.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    255. Caudle AS, Yu TK, Tucker SL, Bedrosian I, Litton JK, Gonzalez-Angulo AM, Hoffman K, Meric-Bernstam F, Hunt KK, Buchholz TA, Mittendorf EA. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res. 2012 May 23; 14(3):R83. PMID: 22621334; PMCID: PMC3446346.
      Citations: 41     Fields:    Translation:Humans
    256. Dominici LS, Mittendorf EA, Wang X, Liu J, Kuerer HM, Hunt KK, Brewster A, Babiera GV, Buchholz TA, Meric-Bernstam F, Bedrosian I. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. Breast Cancer Res. 2012 May 23; 14(3):R82. PMID: 22621306; PMCID: PMC3446345.
      Citations: 16     Fields:    Translation:Humans
    257. Mittendorf EA, Alatrash G, Qiao N, Wu Y, Sukhumalchandra P, St John LS, Philips AV, Xiao H, Zhang M, Ruisaard K, Clise-Dwyer K, Lu S, Molldrem JJ. Breast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anticancer adaptive immune response. Cancer Res. 2012 Jul 01; 72(13):3153-62. PMID: 22564522; PMCID: PMC3397251.
      Citations: 44     Fields:    Translation:HumansCells
    258. Alatrash G, Ono Y, Sergeeva A, Sukhumalchandra P, Zhang M, St John LS, Yang TH, Ruisaard K, Armistead PM, Mittendorf EA, He H, Qiao N, Rodriguez-Cruz T, Liang S, Clise-Dwyer K, Wieder ED, Lizee G, Lu S, Molldrem JJ. The role of antigen cross-presentation from leukemia blasts on immunity to the leukemia-associated antigen PR1. J Immunother. 2012 May; 35(4):309-20. PMID: 22495388; PMCID: PMC3326226.
      Citations: 16     Fields:    Translation:HumansCells
    259. Clive KS, Tyler JA, Clifton GT, Holmes JP, Ponniah S, Peoples GE, Mittendorf EA. The GP2 peptide: a HER2/neu-based breast cancer vaccine. J Surg Oncol. 2012 Apr 01; 105(5):452-8. PMID: 22441896.
      Citations: 18     Fields:    Translation:HumansCells
    260. Kuerer HM, Lari SA, Arun BK, Hu CY, Brewster A, Mittendorf EA, Albarracin CT, Babiera GV, Caudle AS, Wagner JL, Litton JK, Bedrosian I, Meric-Bernstam F, Lucci A, Hunt KK. Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat. 2012 Jun; 133(3):1131-41. PMID: 22392043; PMCID: PMC3855009.
      Citations: 5     Fields:    Translation:Humans
    261. Chawla A, Hunt KK, Mittendorf EA. Surgical considerations in patients receiving neoadjuvant systemic therapy. Future Oncol. 2012 Mar; 8(3):239-50. PMID: 22409461.
      Citations: 3     Fields:    Translation:Humans
    262. Abbott DE, Brouquet A, Mittendorf EA, Andreou A, Meric-Bernstam F, Valero V, Green MC, Kuerer HM, Curley SA, Abdalla EK, Hunt KK, Vauthey JN. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery. 2012 May; 151(5):710-6. PMID: 22285778; PMCID: PMC3628698.
      Citations: 36     Fields:    Translation:Humans
    263. Yi M, Meric-Bernstam F, Kuerer HM, Mittendorf EA, Bedrosian I, Lucci A, Hwang RF, Crow JR, Luo S, Hunt KK. Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol. 2012 Feb 20; 30(6):600-7. PMID: 22253459; PMCID: PMC3295558.
      Citations: 40     Fields:    Translation:Humans
    264. Yi M, Liu P, Li X, Mittendorf EA, He J, Ren Y, Nayeemuddin K, Hunt KK. Comparative analysis of clinicopathologic features, treatment, and survival of Asian women with a breast cancer diagnosis residing in the United States. Cancer. 2012 Sep 01; 118(17):4117-25. PMID: 22460701.
      Citations: 17     Fields:    Translation:Humans
    265. Mittendorf EA, Hunt KK, Boughey JC, Bassett R, Degnim AC, Harrell R, Yi M, Meric-Bernstam F, Ross MI, Babiera GV, Kuerer HM, Hwang RF. Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg. 2012 Jan; 255(1):109-15. PMID: 22167004; PMCID: PMC4760742.
      Citations: 41     Fields:    Translation:Humans
    266. Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, Palla SL, Tokuda Y, Gonzalez-Angulo AM, Hortobagyi GN, Ueno NT. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol. 2012 Feb 20; 30(6):593-9. PMID: 22124109; PMCID: PMC3295557.
      Citations: 148     Fields:    Translation:Humans
    267. Yi M, Mittendorf EA, Cormier JN, Buchholz TA, Bilimoria K, Sahin AA, Hortobagyi GN, Gonzalez-Angulo AM, Luo S, Buzdar AU, Crow JR, Kuerer HM, Hunt KK. Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol. 2011 Dec 10; 29(35):4654-61. PMID: 22084362; PMCID: PMC3236648.
      Citations: 33     Fields:    Translation:Humans
    268. Mittendorf EA, Clifton GT, Holmes JP, Clive KS, Patil R, Benavides LC, Gates JD, Sears AK, Stojadinovic A, Ponniah S, Peoples GE. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer. 2012 May 15; 118(10):2594-602. PMID: 21989902; PMCID: PMC3428069.
      Citations: 63     Fields:    Translation:HumansCellsCTClinical Trials
    269. Adkins FC, Gonzalez-Angulo AM, Lei X, Hernandez-Aya LF, Mittendorf EA, Litton JK, Wagner J, Hunt KK, Woodward WA, Meric-Bernstam F. Triple-negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol. 2011 Oct; 18(11):3164-73. PMID: 21947595; PMCID: PMC4337779.
      Citations: 29     Fields:    Translation:Humans
    270. Sears AK, Perez SA, Clifton GT, Benavides LC, Gates JD, Clive KS, Holmes JP, Shumway NM, Van Echo DC, Carmichael MG, Ponniah S, Baxevanis CN, Mittendorf EA, Papamichail M, Peoples GE. AE37: a novel T-cell-eliciting vaccine for breast cancer. Expert Opin Biol Ther. 2011 Nov; 11(11):1543-50. PMID: 21895539.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    271. Caudle AS, Hunt KK, Kuerer HM, Meric-Bernstam F, Lucci A, Bedrosian I, Babiera GV, Hwang RF, Ross MI, Feig BW, Hoffman K, Litton JK, Sahin AA, Yang W, Hortobagyi GN, Buchholz TA, Mittendorf EA. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol. 2011 Sep; 18(9):2407-12. PMID: 21327455; PMCID: PMC4332388.
      Citations: 33     Fields:    Translation:HumansCells
    272. Nagar H, Mittendorf EA, Strom EA, Perkins GH, Oh JL, Tereffe W, Woodward WA, Gonzalez-Angulo AM, Hunt KK, Buchholz TA, Yu TK. Local-regional recurrence with and without radiation therapy after neoadjuvant chemotherapy and mastectomy for clinically staged T3N0 breast cancer. Int J Radiat Oncol Biol Phys. 2011 Nov 01; 81(3):782-7. PMID: 21885207.
      Citations: 19     Fields:    Translation:Humans
    273. Wu Y, Mittendorf EA, Kelten C, Tucker SL, Wei W, Middleton LP, Broglio K, Buchholz TA, Hunt KK, Sahin AA. Occult axillary lymph node metastases do not have prognostic significance in early stage breast cancer. Cancer. 2012 Mar 15; 118(6):1507-14. PMID: 22009292.
      Citations: 1     Fields:    Translation:Humans
    274. Akay CL, Meric-Bernstam F, Hunt KK, Grubbs EG, Bedrosian I, Tucker SL, Kuerer HM, Hoffman KE, Babiera GV, Strom EA, Buchholz TA, Mittendorf EA. Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol. 2012 Mar; 19(3):901-7. PMID: 21861223; PMCID: PMC6086605.
      Citations: 16     Fields:    Translation:Humans
    275. Mittendorf EA, Smith BD. Locoregional treatment of breast cancer: where to next? Oncology (Williston Park). 2011 Aug; 25(9):817, 821-2. PMID: 21936443.
      Citations:    Fields:    Translation:Humans
    276. Theriault RL, Litton JK, Mittendorf EA, Chen H, Meric-Bernstam F, Chavez-Macgregor M, Morrow PK, Woodward WA, Sahin A, Hortobagyi GN, Gonzalez-Angulo AM. Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. Clin Breast Cancer. 2011 Oct; 11(5):325-31. PMID: 21764391; PMCID: PMC4104010.
      Citations: 24     Fields:    Translation:Humans
    277. Caudle AS, Hunt KK, Mittendorf EA. Response to the letter to the editor: Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: a practice-changing trial. Ann Surg Oncol. 2011 Dec; 18 Suppl 3:S283. PMID: 21725683.
      Citations: 1     Fields:    Translation:HumansCells
    278. Wagner JL, Warneke CL, Mittendorf EA, Bedrosian I, Babiera GV, Kuerer HM, Hunt KK, Yang W, Sahin AA, Meric-Bernstam F. Delays in primary surgical treatment are not associated with significant tumor size progression in breast cancer patients. Ann Surg. 2011 Jul; 254(1):119-24. PMID: 21494124; PMCID: PMC4345121.
      Citations: 20     Fields:    Translation:Humans
    279. Mittendorf EA, Alatrash G, Xiao H, Clifton GT, Murray JL, Peoples GE. Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials. Expert Rev Vaccines. 2011 Jun; 10(6):755-74. PMID: 21692698.
      Citations: 4     Fields:    Translation:Humans
    280. Sharma R, Rourke LL, Kronowitz SJ, Oh JL, Lucci A, Litton JK, Robb GL, Babiera GV, Mittendorf EA, Hunt KK, Kuerer HM. Management of local-regional recurrence following immediate breast reconstruction in patients with early breast cancer treated without postmastectomy radiotherapy. Plast Reconstr Surg. 2011 May; 127(5):1763-1772. PMID: 21532405.
      Citations: 4     Fields:    Translation:Humans
    281. Mittendorf EA, Jeruss JS, Tucker SL, Kolli A, Newman LA, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol. 2011 May 20; 29(15):1956-62. PMID: 21482989; PMCID: PMC3107758.
      Citations: 35     Fields:    Translation:Humans
    282. Roses RE, Arun BK, Lari SA, Mittendorf EA, Lucci A, Hunt KK, Kuerer HM. Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death. Ann Surg Oncol. 2011 Oct; 18(10):2873-8. PMID: 21476105.
      Citations: 14     Fields:    Translation:Humans
    283. Caudle AS, Gonzalez-Angulo AM, Hunt KK, Pusztai L, Kuerer HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer. Ann Surg Oncol. 2011 Apr; 18(4):932-8. PMID: 21061075; PMCID: PMC4347926.
      Citations: 11     Fields:    Translation:Humans
    284. Benavides LC, Sears AK, Gates JD, Clifton GT, Clive KS, Carmichael MG, Holmes JP, Mittendorf EA, Ponniah S, Peoples GE. Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines. Expert Rev Vaccines. 2011 Feb; 10(2):201-10. PMID: 21332269.
      Citations: 7     Fields:    Translation:Humans
    285. Clifton GT, Sears AK, Clive KS, Holmes JP, Mittendorf EA, Ioannides CG, Ponniah S, Peoples GE. Folate receptor a: a storied past and promising future in immunotherapy. Hum Vaccin. 2011 Feb; 7(2):183-90. PMID: 21321484.
      Citations: 11     Fields:    Translation:HumansCells
    286. Valero V, Kong AL, Hunt KK, Yi M, Hwang RF, Meric-Bernstam F, Bedrosian I, Ross MI, Babiera GV, Litton JK, Mittendorf EA. Sentinel lymph node dissection is technically feasible in older breast cancer patients. Clin Breast Cancer. 2010 Dec 01; 10(6):477-82. PMID: 21147692.
      Citations: 2     Fields:    Translation:Humans
    287. Baena-Canada JM, Estalella S, Rosado P. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer. 2011 Apr 15; 117(8):1783; author reply 1783-4. PMID: 21472726.
      Citations: 1     Fields:    Translation:Humans
    288. Boughey JC, Mittendorf EA, Solin LJ, Michael Dixon J, Tuttle TM, Beitsch PD, Cody HS, Leitch AM, Newman LA. Controversies in breast surgery. Ann Surg Oncol. 2010 Oct; 17 Suppl 3:230-2. PMID: 20853038.
      Citations: 4     Fields:    Translation:Humans
    289. Yi M, Giordano SH, Meric-Bernstam F, Mittendorf EA, Kuerer HM, Hwang RF, Bedrosian I, Rourke L, Hunt KK. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol. 2010 Oct; 17 Suppl 3:343-51. PMID: 20853057; PMCID: PMC4324560.
      Citations: 51     Fields:    Translation:Humans
    290. Kang T, Yi M, Hunt KK, Mittendorf EA, Babiera GV, Kuerer H, Bedrosian I, Hwang RF, Lucci A, Meric-Bernstam F. Does blue dye contribute to success of sentinel node mapping for breast cancer? Ann Surg Oncol. 2010 Oct; 17 Suppl 3:280-5. PMID: 20853047; PMCID: PMC4341979.
      Citations: 10     Fields:    Translation:Humans
    291. Holmes JP, Clifton GT, Patil R, Benavides LC, Gates JD, Stojadinovic A, Mittendorf EA, Ponniah S, Peoples GE. Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer. 2011 Feb 01; 117(3):463-71. PMID: 20845479.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    292. Kuerer HM, Buzdar AU, Mittendorf EA, Esteva FJ, Lucci A, Vence LM, Radvanyi L, Meric-Bernstam F, Hunt KK, Symmans WF. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer. 2011 Jan 01; 117(1):39-47. PMID: 20740500; PMCID: PMC2997136.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    293. Yi M, Hunt KK, Arun BK, Bedrosian I, Barrera AG, Do KA, Kuerer HM, Babiera GV, Mittendorf EA, Ready K, Litton J, Meric-Bernstam F. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila). 2010 Aug; 3(8):1026-34. PMID: 20647335; PMCID: PMC4340054.
      Citations: 55     Fields:    Translation:Humans
    294. Dominici LS, Negron Gonzalez VM, Buzdar AU, Lucci A, Mittendorf EA, Le-Petross HT, Babiera GV, Meric-Bernstam F, Hunt KK, Kuerer HM. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer. 2010 Jun 15; 116(12):2884-9. PMID: 20564395; PMCID: PMC4361091.
      Citations: 44     Fields:    Translation:Humans
    295. Bedrosian I, Babiera GV, Mittendorf EA, Kuerer HM, Pantoja L, Hunt KK, Krishnamurthy S, Meric-Bernstam F. A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. Cancer. 2010 Jun 01; 116(11):2543-8. PMID: 20336790; PMCID: PMC4406355.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    296. Sharma R, Bedrosian I, Lucci A, Hwang RF, Rourke LL, Qiao W, Buchholz TA, Kronowitz SJ, Krishnamurthy S, Babiera GV, Gonzalez-Angulo AM, Meric-Bernstam F, Mittendorf EA, Hunt KK, Kuerer HM. Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol. 2010 Nov; 17(11):2899-908. PMID: 20443145; PMCID: PMC4324592.
      Citations: 26     Fields:    Translation:Humans
    297. Clive KS, Tyler JA, Clifton GT, Holmes JP, Mittendorf EA, Ponniah S, Peoples GE. Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental? Expert Rev Vaccines. 2010 May; 9(5):519-25. PMID: 20450326.
      Citations: 24     Fields:    Translation:Humans
    298. Caudle AS, Gonzalez-Angulo AM, Hunt KK, Liu P, Pusztai L, Symmans WF, Kuerer HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010 Apr 10; 28(11):1821-8. PMID: 20231683; PMCID: PMC2860366.
      Citations: 57     Fields:    Translation:Humans
    299. Silberfein EJ, Hunt KK, Broglio K, Shen J, Sahin A, Le-Petross H, Oh J, Litton J, Hwang RF, Mittendorf EA. Clinicopathologic factors associated with involved margins after breast-conserving surgery for invasive lobular carcinoma. Clin Breast Cancer. 2010 Feb; 10(1):52-8. PMID: 20133259.
      Citations: 2     Fields:    Translation:Humans
    300. Carmichael MG, Benavides LC, Holmes JP, Gates JD, Mittendorf EA, Ponniah S, Peoples GE. Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04. Cancer. 2010 Jan 15; 116(2):292-301. PMID: 19924797.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    301. Mittendorf EA, Sharma P. Mechanisms of T-cell inhibition: implications for cancer immunotherapy. Expert Rev Vaccines. 2010 Jan; 9(1):89-105. PMID: 20021308.
      Citations: 15     Fields:    Translation:HumansCells
    302. Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, Esteva FJ, Buzdar AU, Chen H, Eksambi S, Hortobagyi GN, Baselga J, Gonzalez-Angulo AM. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res. 2009 Dec 01; 15(23):7381-8. PMID: 19920100; PMCID: PMC2788123.
      Citations: 121     Fields:    Translation:HumansCells
    303. Hunt KK, Yi M, Mittendorf EA, Guerrero C, Babiera GV, Bedrosian I, Hwang RF, Kuerer HM, Ross MI, Meric-Bernstam F. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009 Oct; 250(4):558-66. PMID: 19730235.
      Citations: 72     Fields:    Translation:Humans
    304. Mittendorf EA, Hunt KK. Lymphatic interrupted: do we really understand the risks and consequences? Ann Surg Oncol. 2009 Jul; 16(7):1768-70. PMID: 19352776; PMCID: PMC2695871.
      Citations: 2     Fields:    Translation:Humans
    305. Benavides LC, Gates JD, Carmichael MG, Patil R, Patel R, Holmes JP, Hueman MT, Mittendorf EA, Craig D, Stojadinovic A, Ponniah S, Peoples GE. The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res. 2009 Apr 15; 15(8):2895-904. PMID: 19351776.
      Citations: 45     Fields:    Translation:HumansCTClinical Trials
    306. Mittendorf EA, Holmes JP, Murray JL, von Hofe E, Peoples GE. CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37). Expert Opin Biol Ther. 2009 Jan; 9(1):71-8. PMID: 19063694.
      Citations: 5     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    307. Grubbs EG, Mittendorf EA, Perrier ND, Lee JE. Gamma probe identification of normal parathyroid glands during central neck surgery can facilitate parathyroid preservation. Am J Surg. 2008 Dec; 196(6):931-5; discussion 935-6. PMID: 19095112.
      Citations: 10     Fields:    Translation:Humans
    308. Holmes JP, Gates JD, Benavides LC, Hueman MT, Carmichael MG, Patil R, Craig D, Mittendorf EA, Stojadinovic A, Ponniah S, Peoples GE. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer. 2008 Oct 01; 113(7):1666-75. PMID: 18726994.
      Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
    309. Mittendorf EA, Sahin AA, Tucker SL, Meric-Bernstam F, Yi M, Nayeemuddin KM, Babiera GV, Ross MI, Feig BW, Kuerer HM, Hunt KK. Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients. Ann Surg Oncol. 2008 Dec; 15(12):3369-77. PMID: 18815841; PMCID: PMC4331098.
      Citations: 15     Fields:    Translation:HumansCells
    310. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Staging of breast cancer in the neoadjuvant setting. Cancer Res. 2008 Aug 15; 68(16):6477-81. PMID: 18701468; PMCID: PMC4441792.
      Citations: 12     Fields:    Translation:Humans
    311. Holmes JP, Benavides LC, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, Murray JL, Amin A, Craig D, von Hofe E, Ponniah S, Peoples GE. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol. 2008 Jul 10; 26(20):3426-33. PMID: 18612158.
      Citations: 34     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    312. Mittendorf EA, Holmes JP, Ponniah S, Peoples GE. The E75 HER2/neu peptide vaccine. Cancer Immunol Immunother. 2008 Oct; 57(10):1511-21. PMID: 18536917; PMCID: PMC11029853.
      Citations: 36     Fields:    Translation:Humans
    313. Amin A, Benavides LC, Holmes JP, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, Storrer CE, Jama YH, Craig D, Stojadinovic A, Ponniah S, Peoples GE. Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer Immunol Immunother. 2008 Dec; 57(12):1817-25. PMID: 18392824; PMCID: PMC11031077.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    314. Mittendorf EA, Lim SJ, Schacherer CW, Lucci A, Cormier JN, Mansfield PF, Gershenwald JE, Ross MI, Lee JE. Melanoma adrenal metastasis: natural history and surgical management. Am J Surg. 2008 Mar; 195(3):363-8; discussion 368-9. PMID: 18206850.
      Citations: 20     Fields:    Translation:Humans
    315. Reed DN, Littman TA, Anderson CI, Dirani GR, Gauvin JM, Apelgren KN, Slomski CA. What is an hour-lecture worth? Am J Surg. 2008 Mar; 195(3):379-81; discussion 381. PMID: 18308042.
      Citations: 3     Fields:    Translation:Humans
    316. Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, Dehqanzada ZA, Gurney JM, Woll MM, Ryan GB, Storrer CE, Craig D, Ioannides CG, Ponniah S. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res. 2008 Feb 01; 14(3):797-803. PMID: 18245541.
      Citations: 50     Fields:    Translation:HumansCellsCTClinical Trials
    317. Stojadinovic A, Nissan A, Shriver CD, Mittendorf EA, Akin MD, Dickerson V, Lenington S, Platt LD, Stavros T, Goldstein SR, Moskovitz O, Gallimidi Z, Fields SI, Yeshaya A, Allweis TM, Manassa R, Pappo I, Ginor RX, D'Agostino RB, Gur D. Electrical impedance scanning as a new breast cancer risk stratification tool for young women. J Surg Oncol. 2008 Feb 01; 97(2):112-20. PMID: 18050282.
      Citations: 10     Fields:    Translation:Humans
    318. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol. 2008 Jan 10; 26(2):246-52. PMID: 18056680.
      Citations: 49     Fields:    Translation:Humans
    319. Mittendorf EA, Peoples GE, Singletary SE. Breast cancer vaccines: promise for the future or pipe dream? Cancer. 2007 Oct 15; 110(8):1677-86. PMID: 17763371.
      Citations: 12     Fields:    Translation:Humans
    320. Stojadinovic A, Henry LR, Peoples GE, Mittendorf EA, Lenington S, Nissan A, Shriver CD. Satisfaction with breast cancer screening and future screening participation. Med Sci Monit. 2007 Oct; 13(10):CR422-9. PMID: 17901848.
      Citations:    Fields:    Translation:HumansPHPublic Health
    321. Mittendorf EA, Hunt KK. Significance and management of micrometastases in patients with breast cancer. Expert Rev Anticancer Ther. 2007 Oct; 7(10):1451-61. PMID: 17944569.
      Citations: 6     Fields:    Translation:Humans
    322. Doherty DB, Mittendorf EA, Valentine AD, Perrier ND. An elderly woman with primary hyperparathyroidism exhibits improvement of neurocognitive dysfunction after parathyroidectomy. J Am Geriatr Soc. 2007 Oct; 55(10):1689-91. PMID: 17908077.
      Citations: 3     Fields:    Translation:Humans
    323. Stojadinovic A, Mittendorf EA, Holmes JP, Amin A, Hueman MT, Ponniah S, Peoples GE. Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study. Ann Surg Oncol. 2007 Dec; 14(12):3359-68. PMID: 17906897.
      Citations: 6     Fields:    Translation:HumansCells
    324. Mittendorf EA, Wefel JS, Meyers CA, Doherty D, Shapiro SE, Lee JE, Evans DB, Perrier ND. Improvement of sleep disturbance and neurocognitive function after parathyroidectomy in patients with primary hyperparathyroidism. Endocr Pract. 2007 Jul-Aug; 13(4):338-44. PMID: 17669708.
      Citations: 10     Fields:    Translation:Humans
    325. Mittendorf EA, Wang X, Perrier ND, Francis AM, Edeiken BS, Shapiro SE, Lee JE, Evans DB. Followup of patients with papillary thyroid cancer: in search of the optimal algorithm. J Am Coll Surg. 2007 Aug; 205(2):239-47. PMID: 17660070.
      Citations: 3     Fields:    Translation:Humans
    326. Mittendorf EA, Evans DB, Lee JE, Perrier ND. Pheochromocytoma: advances in genetics, diagnosis, localization, and treatment. Hematol Oncol Clin North Am. 2007 Jun; 21(3):509-25; ix. PMID: 17548037.
      Citations: 12     Fields:    Translation:Humans
    327. Mittendorf EA, Khiyami A, McHenry CR. When fine-needle aspiration biopsy cannot exclude papillary thyroid cancer: a therapeutic dilemma. Arch Surg. 2006 Oct; 141(10):961-6; discussion 966. PMID: 17043273.
      Citations: 3     Fields:    Translation:Humans
    328. Mittendorf EA, Shifrin AL, Inabnet WB, Libutti SK, McHenry CR, Demeure MJ. Islet cell tumors. Curr Probl Surg. 2006 Oct; 43(10):685-765. PMID: 17055796.
      Citations: 1     Fields:    Translation:Humans
    329. Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE. Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer. Ann Surg Oncol. 2006 Aug; 13(8):1085-98. PMID: 16865596.
      Citations: 26     Fields:    Translation:HumansCellsCTClinical Trials
    330. Mittendorf EA, Storrer CE, Foley RJ, Harris K, Jama Y, Shriver CD, Ponniah S, Peoples GE. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Cancer. 2006 Jun 01; 106(11):2309-17. PMID: 16596621.
      Citations: 21     Fields:    Translation:HumansCellsCTClinical Trials
    331. Mittendorf EA, Gurney JM, Storrer CE, Shriver CD, Ponniah S, Peoples GE. Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer. Surgery. 2006 Mar; 139(3):407-18. PMID: 16546506.
      Citations: 13     Fields:    Translation:HumansCells
    332. Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE. Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides. Breast Cancer Res Treat. 2005 Jul; 92(1):85-93. PMID: 15980996.
      Citations: 25     Fields:    Translation:HumansCells
    333. Mittendorf EA, Arciero CA, Gutchell V, Hooke J, Shriver CD. Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy. Curr Surg. 2005 Mar-Apr; 62(2):253-7. PMID: 15796952.
      Citations: 20     Fields:    Translation:Humans
    334. Mittendorf EA, Goel A, Seaman D. Image of the month. Cholecystocolonic fistula. Arch Surg. 2004 Aug; 139(8):907. PMID: 15302703.
      Citations: 2     Fields:    Translation:Humans
    335. Kennedy JS, Hanly E, Marohn MR, Arciero C, Mittendorf EA. Management of giant gastric ulcers: case report and review of the literature. Curr Surg. 2004 Mar-Apr; 61(2):220-3. PMID: 15051268.
      Citations:    Fields:    Translation:Humans
    336. Mittendorf EA, Merlino JI, McHenry CR. Post-parathyroidectomy hypocalcemia: incidence, risk factors, and management. Am Surg. 2004 Feb; 70(2):114-9; discussion 119-20. PMID: 15011912.
      Citations: 43     Fields:    Translation:Humans
    337. Mittendorf EA, McHenry CR. Complications and sequelae of thyroidectomy and an analysis of surgeon experience and outcome. Surg Technol Int. 2004; 12:152-7. PMID: 15455320.
      Citations: 9     Fields:    Translation:Humans
    338. Onders RP, Mittendorf EA. Utility of laparoscopy in chronic abdominal pain. Surgery. 2003 Oct; 134(4):549-52; discussion 552-4. PMID: 14605614.
      Citations: 18     Fields:    Translation:Humans
    339. Mittendorf EA, Tamarkin SW, McHenry CR. The results of ultrasound-guided fine-needle aspiration biopsy for evaluation of nodular thyroid disease. Surgery. 2002 Oct; 132(4):648-53; discussion 653-4. PMID: 12407349.
      Citations: 20     Fields:    Translation:Humans
    340. Mittendorf EA, McHenry CR, Smith CM, Yowler CJ, Peerless JR. Early and late outcome of bedside percutaneous tracheostomy in the intensive care unit. Am Surg. 2002 Apr; 68(4):342-6; discussion 346-7. PMID: 11952244.
      Citations: 2     Fields:    Translation:Humans
    341. Mittendorf EA, McHenry CR. Persistent parathyroid hormone elevation following curative parathyroidectomy for primary hyperparathyroidism. Arch Otolaryngol Head Neck Surg. 2002 Mar; 128(3):275-9. PMID: 11886343.
      Citations: 14     Fields:    Translation:Humans
    342. Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target. Leukemia.
    343. Operative and Oncologic Outcomes in 9861 Patients with Operable Breast Cancer. Annals of Surgical Oncology. 1-9.
    344. Improved survival of HER2+ breast cancer patients treated with trastuzumab and chemotherapy is associated with host antibody immunity against the HER2 intracellular domain. Cancer Research. 76:3702-3710.
    345. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence. Oncotarget. 7:66192-66201.
    346. Reply to K.J. Van Zee et al. Journal of Clinical Oncology. 30:3144-3145.
    347. Intradermal administration of fluorescent contrast agents for delivery to axillary lymph nodes.
    348. Following the data. ONCOLOGY (United States). 28.
    349. Incorporating the results of the American College of Surgeons Oncology Group Z0011 trial into clinical practice. Current Breast Cancer Reports. 6:17-23.
    350. Clinical Development of the E75 Vaccine in Breast Cancer. Breast Care. 11:116-121.
    351. Immune checkpoints. OncoImmunology. 3.
    352. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment. 1-8.
    353. Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery. Journal of Clinical Oncology. 33:3386-3393.
    354. Clinical practice implementation of findings from the American College of Surgeons Oncology Group Z0010 and Z0011 trials. Breast Diseases. 22:115-118.
    355. Predicting the Extent of Nodal Disease in Early-Stage Breast Cancer. Annals of Surgical Oncology.
    356. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. Annals of Oncology. 27:1241-1248.
    357. Should local therapy for invasive breast cancer be customized on the basis of subtype?. Current Breast Cancer Reports. 5:145-151.
    358. Impact of breast cancer subtypes on local-regional outcomes. Current Breast Cancer Reports. 2:107-113.
    359. Cancer vaccines in the new era of cancer immunotherapy. Vaccine. 33:7376.
    360. Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients. Annals of Surgical Oncology. 1-7.
    361. Adjuvant breast cancer vaccine improves disease specific survival of breast cancer patients with depressed lymphocyte immunity. Breast Diseases. 25:90-92.
    362. Young women with locally advanced breast cancer who achieve breast conservation after neoadjuvant chemotherapy have a low local recurrence rate. Breast Diseases. 23:100-101.
    363. Improved axillary evaluation following neoadjuvant therapy for patientswith node-positive breast cancer using selective evaluation of clipped nodes. Journal of Clinical Oncology. 34:1072-1078.
    364. Consensus nomenclature for CD8+ T cell phenotypes in cancer. OncoImmunology. 4.
    365. HER-2/neu Peptide Breast Cancer Vaccines. Breast Diseases. 17:318-320.
    366. Trends and controversies in multidisciplinary care of the patient with breast cancer. Current Problems in Surgery.
    367. Response to letter to the editor. Annals of Surgical Oncology. 16:2661.
    368. Overcoming cancer tolerance with immune checkpoint blockade. 87-129.
    369. Neutrophil elastase enhances antigen presentation by upregulating human leukocyte antigen class I expression on tumor cells. Cancer Immunology, Immunotherapy. 1-11.
    370. Peptide vaccine strategies in the treatment of cancer. Journal of Proteomics and Bioinformatics. 6:81-84.
    371. Erratum. PLoS One. 11.
    372. Breast Cancer Vaccines. Breast Diseases. 26:279-281.
    373. Ability to generate patient-derived Breast cancer xenografts is enhanced in chemoresistant disease and predicts poor patient outcomes. PLoS One. 10.
    374. Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy. Annals of Surgical Oncology. 1-8.
    375. Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group. Annals of Surgical Oncology. 1-7.
    376. Locoregional treatment of breast cancer. Oncology. 25.
    377. Cyclin e amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Breast Diseases. 22:266-267.
    378. Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy. World Journal of Clinical Oncology. 7:387-394.
    379. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Breast Diseases. 24:55-56.
    380. Prognostic value of axillary lymph node status after neoadjuvant chemotherapy. Results from a multicentre study. Breast Diseases. 22:382-383.
    381. Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer. Annals of Surgical Oncology. 1-9.
    382. Use of a Magnetic Tracer for Sentinel Lymph Node Detection in Early-Stage Breast Cancer Patients. Annals of Surgical Oncology. 23:1508-1514.
    383. Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden. Breast Diseases. 25:54-55.
    384. The development and use of the E75 (HER2 369-377) peptide vaccine. Future Oncology. 12:1321-1329.
    385. Image of the month. Archives of Surgery. 139:907-908.
    386. The clinical impact and outcomes of immunohistochemistry-only metastasis in breast cancer. Breast Diseases. 22:67-68.
    387. Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer. Annals of Surgery.
    388. In Brief. Current Problems in Surgery.
    389. Annals of Surgery.
    390. Injecting hope-A review of breast cancer vaccines. ONCOLOGY (United States). 30.
    391. Toward nodal staging of axillary lymph node basins through intradermal administration of fluorescent imaging agents. Biomedical Optics Express. 5:183-196.
    392. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy. Annals of Surgical Oncology. 23:749-756.
    393. Safety and preliminary evidence of biologic efficacy of a mammaglobin-A DNA vaccine in patients with stable metastatic breast cancer. Breast Diseases. 26:146-147.
    MITTENDORF's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (612)
    Explore
    _
    Co-Authors (147)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _